Society of Biological Psychiatry

65th Annual MeetingMay 20-22, 2010Sheraton New OrleansNew Orleans, Louisiana

Program Book

1

PROGRAM INDEXPage #

Welcome...................................................................................3About SOBP and Biological Psychiatry......................................4Membership Information............................................................5Paper-Lite Conference..............................................................62010 Award Recipients..............................................................72010 Mentor/Mentee Participants..............................................8Floor Plans..........................................................................9-112011 Annual Meeting Save the Date........................................12Acknowledgements, Miscellaneous Information..................13-142010 Scientific Program Planning Committee..........................152010 Program Information..................................................16-18

Wednesday – May 19 Council Meeting......................................................................19Registration.............................................................................19President’s Reception.............................................................19

Thursday – May 20 Registration............................................................................19Speaker Ready Room.............................................................19Continental Breakfast (7:00-8:00 am)......................................19Plenary Session (8:00-10:15 am).............................................19Presidential Lecture (10:45-11:45 am).....................................20Lunch (11:45-12:30 pm)..........................................................20Symposia (12:30-2:30 pm).................................................20-22Oral Session (12:30-2:00 pm).............................................22-23Publishing Workshop (12:30-2:00 pm).....................................23Symposia (3:00-5:00 pm)...................................................23-25Oral Session (3:00-5:00 pm)...............................................25-26Poster Session (5:00-6:30 pm) ..........................................26-362011 Program Planning Meeting (7:00-9:00 pm)......................36

Friday – May 21 Registration.............................................................................37Speaker Ready Room.............................................................37Continental Breakfast (7:00-8:00 am)......................................37Plenary Session (8:00-10:15 am).............................................37Awards (10:30-10:50 am)........................................................37

Presidential Lecture (10:50-11:50 am).....................................37Lunch......................................................................................37Symposia (12:30-2:30 pm).................................................37-40Late Breaking Oral Session (12:30-2:30 pm)...........................40Symposia (3:00-5:00 pm)...................................................40-42Late Breaking Oral Session (3:00-5:00 pm)........................42-43Funding Workshop (3:00-5:00 pm)..........................................43Poster Session (5:00-6:30 pm) ..........................................46-53Welcome Reception................................................................53

Saturday – May 22 Registration.............................................................................54Speaker Ready Room.............................................................54Continental Breakfast (7:00-8:00 am)......................................54Plenary Session (8:00-10:15 am).............................................54Presidential Lecture (10:45-11:45 am).....................................54Lunch......................................................................................54Symposia (12:30-2:30 pm)................................................54-57Oral Session (12:30-2:30 pm).................................................57Symposia (3:00-5:00 pm)..................................................57-60Oral Session (3:00-5:00 pm)...................................................60Poster Session (5:00-6:30 pm)...........................................60-70

2

Welcome

I am delighted to welcome you to the Annual meeting of our Society of Biological Psychiatry. Together with the Chair of this year’s Program Committee, Stephan Heckers, we present a scientific program that is stimulating and exciting, with important innovations to enhance learning, discussion and networking.

First the presidential plenary sessions are organized around major illness: mood disorders, psychoses and addictions. Each session occupies a morning and all plenaries comprise three speakers on cellular, circuitry and treatment aspects respectively, and finally a major presidential speaker to give an overview of the field emphasizing what is known and what is not known at this time. We have reduced the number of speakers in each morning session to allow the speakers to give more depth and detail.

We have dropped the workshops and increased the number of symposia and oral sessions and have added late-breaking abstracts to each of the poster sessions in addition to the late-breaking oral session. We have tried to avoid clashes in the same time slot of symposia on similar topics or the same disorder, to the degree permitted by distributing the presentations over different days or sessions at different times.

We have special sessions on publishing papers chaired by our own journal’s editor, John Krystal and on research grants chaired by Mark Chavez from NIMH. These sessions are really popular for younger investigators.

We are firmly in the era of translational research. New knowledge from genetics and brain imaging as well as new randomized clinical trials has created the hope of a new classification system for psychiatric disorders and ideas for prevention. Some of the findings reported at this meeting may bring that ambition a little closer.

Stephan Heckers, the Scientific Program Committee Chairman, and I, along with the great efforts of the Society of Biological Psychiatry Program Committee members, have crafted a meeting program that we believe is outstanding in its scope, content, and timeliness. On behalf of the entire 2010 Program Committee, enjoy the meeting and a resurgent and rebuilt New Orleans.

Regards,

J John Mann, MDPresidentSociety of Biological Psychiatry

Stephan Heckers, MDChair, Scientific Program Committee

3

About SOBP

The Society of Biological Psychiatry was founded in l945 to encourage the study of the biological causes of and treatments for psychiatric disorders. Its continuing purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms, and treatments of disorders of thought, emotion, or behavior.

To achieve its purpose, the Society creates venues for the exchange of scientific information that will foster the advancement of psychiatric neuroscience and therapeutics. To this end, the Society sponsors an annual meeting, maintains web-based resources, grants awards to distinguished clinical and basic researchers, and publishes the journal, Biological Psychiatry.

The term “biological psychiatry” emphasizes the biological nature of behavior and its disorders and implies the use of the medical model; but in so doing, it encompasses other major elements of modern psychiatric medicine, including its humanitarian mission, psychological foundation, and socio-cultural orientation.

The vision of the Society of Biological Psychiatry is to be the leading professional organization in the integration, advancement, and promulgation of science relevant to psychiatric disorders, with the ultimate goal of reducing or preventing the suffering of those with these disorders.

Biological Psychiatry – Official Journal of SOBP

Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 4th out of the 101 journals in Psychiatry titles and 14th out of 219 journals in the neurosciences categories on the 2009 Journal Citation Reports® published by Thomson Reuters, and has an Impact Factor of 8.672.

This international rapid-publication journal is the official journal of the Society of Biological Psychiatry. It covers a broad range of topics in psychiatric neuroscience and therapeutics. Both basic and clinical contributions are encouraged from all disciplines and research areas relevant to the pathophysiology and treatment of major neuropsychiatric disorders. Novel results of original research, available in three formats of Archival, Research and Brief Reports, Commentaries and Correspondence judged to be of high impact to the field are published, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Concise Reviews and Editorials that focus on topics of current research and interest are also published rapidly.

4

Membership - Staying Current and Connected

The Society of Biological Psychiatry (SOBP) invites you to join senior and junior psychiatric neuroscientists who are engaged in basic, translational, and clinical science in order to serve people with mental illness.

The Society is a vital and dynamic organization. Founded almost 60 years ago, SOBP has undergone a dramatic scientific renaissance over the past decade. It is a unique Society, where both senior and junior scientists contribute to a stimulating and extremely well-attended meeting. Our Journal, Biological Psychiatry, is now the fourth-ranked journal in Psychiatry in the world (among 94 journals), with an impact factor of 8.456.

When you become a member of this intimate yet cutting edge Society, you will have the opportunity to interact with thought leaders who are fueling innovation, access and development in the field of psychiatric neuroscience including major advances in genetics and therapeutics. Your membership in the Society of Biological Psychiatry will put you in touch with your colleagues who have shaped the field as it currently exists and it will enable you to be one of those who shape biological psychiatry as it will be known!

When we listen to our members talk about what their membership means to them, they most often refer to the intangible benefits, particularly the collegiality of their fellow SOBP members. Personal and professional relationships are built through attending the annual meeting and serving on committees. Many leaders in our field have joined the SOBP over the past 10 years so that the Society is maintaining a balance of new senior and junior members.

The Society of Biological Psychiatry has made it economical and easy to become a member. Since the SOBP has as a major goal the development of young scientists, you can apply for membership with 5 peer-reviewed publications. If you have fewer publications, you can apply for Associate Membership. Residents of the USA, Canada and Mexico (North America) are eligible for “Regular” membership. Residents of other countries can join the Society as a “Corresponding” member.

Whether you apply for Regular, Associate, or Corresponding membership, you will receive the following benefits:

Prestige and increased credibility among peers and the public. Complimentary subscription, both print and online, to Biological Psychiatry, the official publication of the Society

of Biological Psychiatry. All members can register for the Society of Biological Psychiatry’s Annual Meeting for $495. This represents a

significant savings from the full-cost, non-member registration fee! Membership Directory Member’s Only Resources Quarterly Newsletters Participation in leadership and committees All members can participate in online discussions of articles that appear in Biological Psychiatry through

www.sobp.org Annual dues for members are $250 (corresponding and senior members are $200 annually)

For our colleagues who do not reside in North America: We understand that your own Society is, and should be, your main priority, and we urge you to maintain your primary membership in your own Society. We do hope that you will consider joining our Society as a Corresponding Member, attending our Annual Meeting, and receiving our highly acclaimed Journal.

JOIN TODAY – WWW.SOBP.ORG

5

This conference is Paper-Lite

The Society of Biological Psychiatry is committed to reducing the amount of paper we use at our annual meeting in an effort to be responsible toward the environment and to increase the quality and timeliness of the resources provided for this learning experience. Some changes you will notice this year are:

Abstract Book: All attendees will continue to receive a hard copy of the abstracts printed in the Supplement to Biological Psychiatry. Members will receive their abstract book along with their journal subscription in the mail and should bring with them to the meeting. Non-members will receive a copy at the registration desk.

Program Book: The Program Book will be available electronically at www.sobp.org. This book contains a listing of all sessions with each speaker, title and abstract #, time of presentation, along with other information helpful to planning your itinerary and making the most of your time at this meeting. Please review this program book on line and print any sections you may like to bring with you to the meeting.

Meeting-at-a-Glance: All attendees will receive a Meeting-at-a-Glance at the registration desk. This is a fold-out document which will provide an overview of all session titles, times and locations. You can use this document along with your abstract book during the meeting.

ePosters: This year, the Society will offer the option for all poster presenters to upload their poster as an ePoster for viewing electronically immediately before and after the meeting. More information regarding this feature will be announced at the meeting. Poster presenters will be notified shortly before the meeting.

6

Society of Biological PsychiatryCongratulations to our 2010 Award Recipients

7

Humanitarian AwardFor service and advocacy to mental illness

Howard J. Osofsky, MDTulane UniversityNew Orleans, Louisiana

Gold Medal Award To honor pioneering contributions In the field of Biological Psychiatry

Charles P. O’Brien, MD, PhDUniversity of PennsylvaniaPhiladelphia, Pennsylvania

George N. Thompson AwardTo honor members of the Society who have given outstanding service to promote the welfare of the organization

Elliott Richelson, MDMayo ClinicJacksonville, Florida

A. E. Bennett Research AwardTo stimulate research in biological psychiatry by young investigators

Francis Lee, MD, PhDWeill Cornell Medical CollegeNew York, New York(For Basic Research)

David C. Glahn, PhDYale UniversityHartford, CT(For Clinical Research)

Ziskind-Somerfeld Research AwardTo stimulate research in biological psychiatry

Tania Roth, PhDUniversity of AlabamaMcKnight Brain InstituteBirmingham, Alabama

Travel Fellowship AwardFor promising young investigators (within North America) who would benefit from attending the meeting

Ana Andreazza, PhDUniversity of British ColumbiaVancouver, BC, Canada

Kathryn Cullen MDUniversity of MinnesotaMinneapolis, Minnesota

Brian James Mickey, MD, PhDUniversity of MichiganAnn Arbor, Michigan

Daniel Rosell, MD, PhDMount Sinai Medical SchoolNew York, New York

Toral Surti, MD, PhDYale UniversityNew Haven, Connecticut

Aliza Wingo, MDEmory UniversityAtlanta, Georgia

International Travel Fellowship AwardFor promising young investigators (outside of North America) who would benefit from attending the meeting

Michal Arad, MATel-Aviv UniversityTel-Aviv, Israel

Josselin Houenou, MDINSERMCréteil, France

Stefan Kloiber, MDMax-Planck-InstituteMunich, Germany

Valeria Mondelli, MD, PhDKing’s College HospitalLondon, United Kingdom

Dekel Taliaz, MScWeizmann Institute of ScienceRehovot, Israel

8

Society of Biological Psychiatry 2010 Mentor/Mentee Program Participants

The Society of Biological Psychiatry recognizes the importance of mentoring to the professional development of its members. This mentoring program provides opportunities for early-career biological psychiatrists and neuroscientists to benefit from access to more experienced professionals while giving mentors the opportunity to contribute to the future of the neuroscience profession. We are proud to announce our 2010 Mentor/Mentee Program participants:

Mentor MenteePaul E. Holtzheimer, III, MDEmory University

Leah Rubin, MDUniversity of Illinois at Chicago

John Krystal, MDYale University

Jeffrey Bedwell, PhDUniversity of Central Florida

Todd Lencz, PhDAlbert Einstein College of Medicine

Panos Roussos, MD, PhD Mount Sinai School of Medicine

Xiaohua Li, MD, PhD. University of Alabama, Birmingham 

Joel Snyder, PhDUniversity of Nevada, Las Vegas

Helen Lavretsky, MDUniversity of California, Los Angeles

Cecile Ladouceur, PhDUniversity of Pittsburgh

Sandeep Parkhi, MDDeeenanath Mangeshkar Hospital and Research Centre

Rishikesh Behere, MDNIMH

Linda L. Carpenter M.D.Brown University, Butler Hospital

Maria de la Mercedes Perez-Rodriguez, MD, PhDMount Sinai School of Medicine

David R. Rubinow, MDUniversity of North Carolina

S. Evelyn Stewart, MDMass General/Harvard Medical School

Jennifer Lanier Payne M.D.Johns Hopkins School of Medicine

Hazli Zakaria, MBBSKuala Lumpur, Malaysia

Mark Frye, MDMayo Clinic

Jorge Almeida, MD, PhDUniversity of Pittsburgh

Trey Sunderland, MDSociety of Biological Psychiatry

Toral Surti, MD, PhDYale University

Mary Phillips, MDUniversity of Pittsburgh

Mark LechnerBakersfield, CA

9

Floor Plans

2nd Floor

10

3rd Floor

4th Floor

11

5th Floor

8th Floor

12

Save the DateSociety of Biological Psychiatry

66th Annual Scientific ConventionMay 12-14, 2011

San Francisco, California(APA meeting will be meeting in Hawaii)

Famous for scenic beauty, cultural attractions, diverse communities and world-class cuisine, San Francisco’s landmarks include the Golden Gate Bridge, cable cars, Fisherman’s Wharf, Alcatraz, Chinatown, Union Square, North Beach, the Castro district and Mission Dolores. The much-celebrated fog creates a romantic mood in this most European of American cities. Plan now to attend the Society’s meeting in San Francisco!

Call for Abstracts Open September 1, 2010Abstract Deadlines (tentative):October 29, 2010 - Symposia

December 10, 2010 – Poster and Oral Sessionswww.sobp.org

13

J. John Mann, MD PresidentHelen Mayberg, MD Incoming PresidentDavid Rubinow, MD Executive SecretaryTrey Sunderland, MD Incoming Executive SecretaryElliott Richelson, MD Treasurer

Councilors Alan Schatzberg, MDJohn Csernansky, MDScott Rauch, MDPeter Roy-Byrne, MDRaquel Gur, MDHusseini Manji, MDJeffrey Lieberman, MD

Biological Psychiatry

Elliott Richelson, MDMayo Clinic4500 San Pablo Rd – Birdsall 310Jacksonville, FL 32224904-953-2842 Ofc; 904-953-7117 Fax

David Rubinow, MD

(919) 966-4738Ofc; (919) 966-7659Fax

Office of the Executive DirectorMaggie Peterson, MBASociety of Biological PsychiatryC/O Mayo Clinic Jacksonville4500 San Pablo Road, Birdsall 310Jacksonville, FL 32224 (904) 953-2842 Ofc; (904) 953-7117 Faxmaggie@sobp.org, http://www.sobp.org

Future Meeting Dates/LocationsMay 12-14, 2011 – San Francisco, CAMay 8-10, 2012 – Philadelphia, PAMay 16-19, 2013 – San Francisco, CA

14

Past Presidents

J. M. Nielsen,* President 1946-47Percival Bailey,* President 1948S. Bernard Wortis,* President 1949Harry C. Solomon,* President 1950Roland P. McKay,* President 1951Abram E. Bennett,* President 1952Ladislas I. Meduna,* President 1953Harold E. Himwich,* President 1954Howard D. Fabing,* President 1955Margaret A. Kennard,* President 1956Jules H. Masserman,* President 1957Joseph Wortis,* President 1958Paul H. Hoch,* President 1959W. Horsley Gantt,* President 1960Lauretta Bender,* President 1961Paul I. Yakovlev,* President 1962Amedeo S. Marrazzi,* President 1963Max Rinkel,* President 1964D. Ewen Cameron,* President 1965Ralph W. Gerard,* President 1966Hudson Hoagland,* President 1967Robert G. Heath, President 1968George N. Thompson,* President 1969John I. Nurnberger*, President 1970Leo Alexander,* President 1971Jacques S. Gottlieb,* President 1972Williamina A. Himwich,* President 1973Charles Shagass,* President 1974Sabit Gabay, President 1975Arnold J. Mandell, President 1976Robert G. Grenell, President 1977

Iver F. Small, President 1978John P. Brady, President 1979Arnold J. Friedhoff, President 1980Arthur W. Epstein,* President 1981Enoch Callaway, III, President 1982Gerald J. Sarwer-Foner, President 1983Bernard J. Carroll, President 1984Daniel X. Freedman,* President 1985Paula J. Clayton, President 1986Everett H. Ellinwood, Jr.,* President 1987Wagner H. Bridger,* President 1988David J. Kupfer, President 1989Kenneth L. Davis, President 1990John F. Greden, President 1991David L. Dunner, President 1992Joel E. Kleinman, President 1993Elizabeth B. Weller*, President 1994Katherine A. Halmi, President 1995A. John Rush, President 1996David L. Braff, President 1997Daniel R. Weinberger, President 1998Elliott Richelson, President 1999Larry J. Siever, President 2000David Rubinow, President 2001Trey Sunderland, President 2002Harold Sackeim, President 2003Jeffrey Lieberman, President 2004Alan Schatzberg, President 2005 - 2006Peter Roy-Byrne, President 2006 - 2007Raquel Gur, President 2007 – 2008Husseini Manji, 2008-2009

*Deceased

15

2010 Scientific Program Committee Members

J. John Mann, MD - PresidentStephan Heckers, MD – Program Chair

Amit Anand, MDWade Berrettini, MD, PhDZubin Bhagwagar, MDGarth Bissette, PhDAlan Brown, MDE. Sherwood Brown, MD, PhDChristin Cadenhead, MDCameron Carter, MDMiranda Chakos, MDRonald Dahl, MDJose DeLeon, MDLynn DeLisi MDDorcas Dobie, MDYogesh Dwivedi, PhDMichael Egan, MDMary-Anne Enoch, MDJudith Ford, PhDGuido Frank, MDJohn Gilmore, MDRoger Haskett, MDJohn Herman, PhDThomas Hyde, MD, PhDJoel Kleinman, MD, PhDHarold Koenigsberg, MDEllen Leibenluft, MD

Israel Liberzon, MDHusseini Manji, MDChristina Marx, MDHelen Mayberg, MDEric Nestler, MDJohn Neumaier, MD, PhDThomas Nordahl, MD, PhDAnn Olincy, MDGhanshyamPandey, PhDBradley Peterson, MDMaggie Peterson, MBADaniel Pine, MDGretchen Rajkowski, MDUma Rao, MDElliott Richelson, MDChristopher Ross. MD, PhDDavid Rubinow, MDPeter Schmidt, MDLarry Siever, MDStephan Taylor, MDGunvant Thaker, MDMadhukar Trivedi, MDBruce Turetsky, MDCynthia Weickert, PhDCarlos Zarate, MD

16

Program Goals and Objectives

The goal of this meeting is to advance the understanding of and knowledge about the relationship of psychopathology to brain development, genetics, early life adversity, current stressful life events, epigenetic modifications, and brain circuitry, and to identify mechanisms of action of clinically proven treatments and the development and evaluation of novel approaches for treating mental illness.

At the conclusion of this CME activity, the participant should be able to:

Describe and discuss recent advances in treatment strategies for psychiatric disorders. Describe and discuss application of treatment strategies for psychiatric disorders in their clinical

practices and research activities. Describe and discuss recent advances in basic and clinical neuroscience that affect the

development of new treatments and may modify current treatment practices. Describe and discuss recent progress in identifying genetic variations that are risk factors for the

development of psychiatric disorders. Translate basic neuroscience findings of relevance to clinical practice.

Target AudienceThis course is designed for researchers, clinicians, neuroscientists, MDs, PhDs, and young researchers.

AccreditationThis activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of College of Medicine, Mayo Clinic and the Society of Biological Psychiatry. College of Medicine, Mayo Clinic is accredited by the ACCME to provide continuing medical education for physicians.

College of Medicine, Mayo Clinic, designates this educational activity for a maximum of 21.75 AMA PRA Category 1 Credit(s)PP

TMPP. Physicians should only claim credit commensurate with the extent of their

participation in the activity.

NOTE: Due to changes in ACCME accreditation policies regarding presentations made by industry scientists and commercial companies, the Society will not provide AMA PRA Category 1 Credit(s)™ for the poster sessions to allow scientists from industry to participate in these sessions.

Faculty DisclosuresAs a provider accredited by ACCME, College of Medicine, Mayo Clinic (Mayo School of CME) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentation.

A complete list of faculty disclosure is included in this program book. Please review this information and make any necessary updates at the beginning of your talk. In addition, the Society asks that you verbally disclose this information to your audience.

CME Record of AttendanceTo obtain credit, you must:

1. Register and pay for CME credit2. Sign-in each day at the Registration Desk.3. Complete and return the attendance certificate at the end of the program. Credit will not be

provided if the attendance certificate is not returned or lost.

17

FACULTY DISCLOSURE

As a provider accredited by ACCME, College of Medicine, Mayo Clinic (Mayo School of CME) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentation.

Faculty: In addition to the information provided to attendees, we ask that you make a verbal disclosure at the beginning of your presentation and correct or update your disclosure information if necessary.

All faculty disclosure information is available at www.sobp.org

Americans with Disabilities Act The Society of Biological Psychiatry fully complies with the legal requirements of the ADA and the rules and regulations thereof. Please see the Registration Desk if you have any special needs.

Acknowledgement of Commercial SupportThe Society does not seek or accept commercial funding to support this meeting. The entire meeting is supported by registration fees or independent funding by the Society of Biological Psychiatry.

Evaluation FormsThe members of the Scientific Program Committee are interested in your opinion regarding the quality and the content of the Annual Meeting. This information will be used to plan next year’s Annual Meeting. This year, the meeting survey will be electronic and will be sent to your email address immediately after the meeting. Or, visit www.sobp.org to complete the survey.

Recording Sessions/No CamerasAttendees may not videotape, audiotape, or photograph (camera or camera phone) presentations at the meeting without prior permission from the chair of the session. Cameras are not permitted in any educational session or in the poster sessions.

Registration DeskThe Registration Desk will be staffed during the following hours:

Wednesday, May 19 2:00 pm – 5:30 pm Thursday, May 20 7:00 am – 5:00 pmFriday, May 21 7:00 am – 5:00 pmSaturday, May 22 7:00 am – 5:00 pm

Name BadgesName badges will be required for admission to all sessions. A $5 charge will be incurred for replacement badges.

PublicationsAll transactions of the Annual Meeting will be published in the Society’s journal, Biological Psychiatry. These proceedings are not fully peer reviewed and cannot be cited. Additional Abstract books may be purchased for $20 each.

18

Alcohol PolicyThe Society of Biological Psychiatry is legally and ethically obligated to remind participants that alcoholic beverages are a part of some Society of Biological Psychiatry events. An individual’s decision to partake is a matter of personal choice and is neither encouraged nor discouraged by the Society. Reasonable and appropriate measures are taken by the Society to ensure that consumption occurs in a safe and responsible manner. The Society of Biological Psychiatry creates opportunities for its attendees to engage in business with each other. The Society also provides opportunities for friends and colleagues to network and socialize. Irresponsible drinking could undermine these opportunities. All attendees are expected to exercise restraint and good judgment in their consumption of alcohol at Society of Biological Psychiatry events.

Poster SessionsThe poster sessions are from 5:00 pm – 6:30 pm each day. You may hang your poster anytime between 7:00 am and 5:00 pm. The Society is not responsible for posters not taken down promptly after each session.

Annual Business MeetingThe Annual Business Meeting will be held on Friday, May 21, 2010. This will be the only business session of the convention. All members are encouraged to attend and non-members are invited to attend.

Welcome ReceptionFriday, May 21, 20106:45 PM – 8:15 PM

All registered attendees and their guests who have purchased a guest ticket are invited to the Welcome Reception in the Armstrong Ballroom at the Sheraton New Orleans. Please show your attendee name badge or guest ticket for entrance. Cocktails and appetizers will be served. Dress is business casual.

19

Wednesday, May 19

Council MeetingWednesday, May 1911:00 AM – 5:00 PMGallier AB – 4th Floor(Invitation only)

RegistrationWednesday, May 192:00 PM – 5:00 PMGrand Ballroom Foyer – 5th Floor

President’s ReceptionWednesday, May 195:30 PM – 7:00 PMLagniappe – 2nd Floor(Invitation only)

Thursday, May 20

Continental BreakfastThursday, May 207:00 AM – 8:00 AMGrand Ballroom Foyer – 5th Floor

RegistrationThursday, May 207:00 AM – 5:00 PMGrand Ballroom Foyer – 5th Floor

Speaker-Ready RoomThursday, May 207:30 AM – 5:00 PMEdgewood AB – 4th Floor

Legend:Presentation Time...........................Abstract #

Plenary Session - DepressionThursday, May 208:00 AM – 10:15 AMGrand Ballroom – 5th Floor

Chair: Stephan Heckers

8:00 AMAntidepressant Action: From Molecule to Mouse to Man.................................................1Randy D. Blakely, PhDVanderbilt University

8:45 AMThe Cognitive Control of Emotion: From Basic Mechanisms to Mechanistic Breakdowns...................................................2Kevin Ochsner, PhDColumbia University

Theory to Practice: Towards the Use of Neuroimaging in the Diagnosis and Management of Patients with Major Depression.....................................................3Helen S. Mayberg, MD, FRCPCEmory University

BreakThursday, May 2010:15 AM – 10:45 AMGrand Ballroom Foyer – 5th Floor

Presidential Lecture20

Thursday, May 2010:45 AM – 11:45 PMGrand Ballroom – 5th Floor

Chair: Stephan Heckers

Future Perspectives of Depression Research.........................................................4Florian Holsboer, MD, PhDMax Planck Institute of Psychiatry

Lunch/NetworkingThursday, May 2011:45 AM – 12:30 PMGrand Ballroom Foyer – 5th Floor

Box lunches will be available for all registered attendees.

Symposium Molecular Mechanisms Linking Serotonin Neurotransmission to Behaviors in DepressionThursday, May 2012:30 PM - 2:30 PMGrand Couteau - 5th Floor

Chair Xiaohua LiCo-Chair Gwenn S. Smith

12:30 PMP11 Interaction with Serotonin Receptors and its Role in Depression............................5Per Svenningsson

1:00 PMRole of GSK-3 Signaling in Serotonergic Behaviors and the Effects of Mood Stabilizers.......................................................6Martin Beaulieu

1:30 PMRegulation of Stress-Responsive FoxO by Serotonin and Antidepressant......................7Xiaohua Li

2:00 PMMolecular Imaging of Serotonin Function in Geriatric Depression......................................8Gwenn S. Smith

Symposium

The Emerging Neurobiology of Antidepressant Treatment ResponseThursday, May 2012:30 PM - 2:30 PMGrand Chenier - 5th Floor

Chair: Katharina DomschkeCo-Chair: Yvette Sheline

12:30 PMConnectivity of the Subgenual Cortex and HPA Axis in Depression.................................9Alan F. Schatzberg

1:00 PMPrediction of Antidepressant Treatment Response - A Pharmaco- And Imaging Genetic Contribution...................................10Katharina Domschke

1:30 PMThe Role of the Default Mode Network (DMN) in Understanding Emotional Circuitry in MDD Pre- and Post- Antidepressant Treatment.....................................................11Yvette Sheline

2:00 PMFrom Resetting Chemical Dysbalance to Modulating Networks - Lessons on the Neurobiology of Treatment Resistant Depression from Deep Brain Stimulation. . .12Thomas E. Schlaepfer

SymposiumGene Expression Across Human Brain Development and SchizophreniaThursday, May 2012:30 PM - 2:30 PMBayside BC - 4th Floor

Chair: Joel E Kleinman

12:30 PMDysbindin-1 Transcripts and Isoforms are Differentially Affected in Schizophrenia.....13Konrad Talbot

1:00 PMEpigenetic Markings in Developing and Diseased Prefrontal Neurons.......................14Schahram Akbarian

1:30 PMCellular Expression Profiling of Neurotransmitter Receptors in Human

21

Brain.............................................................15Andreas Jeromin

2:00 PMGenetic Regulation of Human Cortical Gene Expression Across the Lifespan.................16Barbara K. Lipska

SymposiumNeuropeptides and Interpersonal PsychopathologyThursday, May 2012:30 PM - 2:30 PMMaurepas - 3rd Floor

Chair: Larry J SieverCo-Chair: Jon-Kar Zubieta

12:30 PMNeural Mechanisms of Prosocial Neuropeptide Action in Human Brain: Challenge and Genetic Studies...................17Andreas S.Meyer-Lindenberg

1:00 PMDopamine-Opioid Interactions in Attachment Style and Impulsivity Traits.........................18Jon-Kar Zubieta

1:30 PMOpioids and Oxytocin: Genotypes and Phenotypes in BPD......................................19Larry J. Siever

2:00 PMAssociation between Endogenous Opioids and Childhood Neglect and Abuse.............20Barbara Stanley

SymposiumRecent Advances in Fmri-Based Functional Connectivity Analysis in Affective DisordersThursday, May 2012:30 PM - 2:30 PMGrand Ballroom ABC

Chair: J. Paul HamilsonCo-Chair: Amit Etkin

12:30 PM

Investigating Neural Primacy in Major Depressive Disorder: Multivariate Granger Causality Analysis of Resting-State fMRI Time-Series Data..........................................21J. Paul Hamilton

1:00 PMConnectivity Analysis in Major Depressive Disorder Using Vector Autoregressive Models of Event-Related fMRI Data.............22Wesley K. Thompson

1:30 PMFronto-Cingulate Effective Connectivity in Major Depression: A Study with FMRI and Dynamic Causal Modeling...........................23Ralf G.M. Schlösser

2:00 PMDisrupted Amygdalar Subregion Functional Connectivity and Evidence for a Compensatory Network in Generalized Anxiety Disorder..........................................24Amit Etkin

SymposiumNeurogenesis, Angiogenesis and Synaptogenesis RegulationThursday, May 2012:30 PM - 2:30 PMBorgne - 3rd Floor

Chair: Maura BoldriniCo-Chair: Victoria Arango

12:30 PMVascular Remodeling Mechanisms in the Hippocampus...............................................25Samuel Sathyanesan

1:00 PMDifferential Effect of Corticosterone on Neurogenesis and Angiogenesis................26Anders Tingström

1:30 PMAntidepressants Increase Neural Progenitor Cells and Capillaries in the Human Dentate Gyrus............................................................27Maura Boldrini

2:00 PMRoles of Bcl-2 Family Proteins and Mood Stabilizer-Induced Changes in Hippocampal Synapses in the Behavioral Regulation Related to Mood Disorders..........................28Guang Chen

Symposium22

Separation Distress in Non-Human Primates, Children, and Adults: Implications for Depression, Anxiety, Panic, and GriefThursday, May 2012:30 PM - 2:30 PMBayside A - 4th Floor

Chair: Peter J. FreedCo-chair: Stephen J Suomi

12:30 PMGxE Interactions Influence Attachment in Non-Human Primates...................................29Stephen J. Suomi

1:00 PMGene and Physiological and Correlates of Social Behavior in Monkeys Experiencing Maternal Separation ....................................30Judy Cameron

1:30 PMThe Neurobiology of Altered Socio-Emotional Behavior in Maternally Deprived Human Children........................................................31Nim Tottenham

2:00 PMAcute Expression of Separation Distress in Adult Humans Alters Activity in Brain Regions Encoding Reward Processing and Separation Distress .....................................32Peter J. Freed

SymposiumCSTC Circuits in the Pathogenesis of ADHDThursday, May 2012:30 PM - 2:30 PMNottoway - 4th Floor

Chair: Bradley S Peterson

12:30 PMPrefrontal Circuits, Psychostimulants, and Default-Mode Processing in ADHD.............33Bradley S Peterson

1:00 PMMorphological Abnormalities of the Basal Ganglia and the Thalamus in ADHD............34Iliyan Ivanov

1:30 PMDevelopmental Upregulation of Dopamine D2 Receptors in the Mouse Striatum Alters the Functioning of the Cortico-Striatal Cicuits...........................................................35Christoph Kellendonk

2:00 PMTonic and Phasic Norepinephrine in Attention-Deficit/Hyperactivity Disorder: Insights from a Neurocomputational Model of the Stroop Task............................................36Tiago V. Maia

Oral Session - SchizophreniaThursday, May 2012:30 PM - 2:30 PMSouthdown - 4th Floor

Chair: See On-Line Program Book

12:30 PMGenetically Determined Measures of Striatal D2 Signaling Predict Prefrontal Activity During Working Memory..............................37Alessandro Bertolino

12:45 PMStatic and Dynamic Cognitive Deficits in Childhood Precede Adult Schizophrenia: A 30-Year Study...............................................38Abraham Reichenberg

1:00 PMGenetic Control Over the Default Mode Network.........................................................39David C. Glahn

1:15 PMA Longitudinal Imaging-Genetics Study of Catechol-O-Methyltransferase Val158Met Genotype and Cortical Maturation in Youth with Childhood-Onset Psychosis, Their Non-Psychotic Siblings and Typically Developing Controls........................................................40Armin Raznahan

1:30 PMMetabotropic Glutamate Receptor and Endocannabinoid Signaling in the Prefrontal Cortex in Schizophrenia..............................41David Volk

23

1:45 PMConvergent Neuroimaging and Neuropsychological Studies of Progressive Decline in Cognitive Performance and Grey Matter Loss in Schizophrenia Following HSV1 Exposure............................................42Konasale M. Prasad

2:00 PMWhy Transition to Psychosis is not the Whole Story - Neurocognitive Markers of Transition and Poor Functional Outcome Seven to 14 Years after Identification as Ultra-High Risk at the PACE Clinic..............43Stephen J. Wood

2:15 PMThe Multidimensional Structure of Processing Speed in Healthy Individuals and Schizophrenia Patients................................44Emma E. Knowles

Workshop - PublishingAsk the Editors: A Workshop on Publishing in Psychiatry.................................................45Thursday, May 2012:30 PM – 2:30 PMOak Alley – 4th Floor

Chair: John-Kar Zubieta

BreakThursday, May 202:30 PM – 3:00 PMGrand Ballroom Foyer – 5th Floor

Symposium Imaging the Mechanisms of Genetic Liability to Bipolar DisorderThursday, May 203:00 PM - 5:00 PMBayside BC - 4th Floor

Chair: Andrew M McIntoshCo-Chair: Melissa DelBello

3:00 PMSpatial Working Memory Related Brain Activation in Individuals with Bipolar Disorder and their Unaffected Siblings.......46David C. Glahn

3:30 PMStructural and Functional Brain Abnormalities in People at High Risk of Bipolar Disorder for Familial Reasons........47Andrew M. McIntosh

4:00 PMNeurofunctional Brain Abnormalities in Adolescents At-Risk for Bipolar Disorder...48Melissa DelBello

4:30 PMThe Functional Consequences of Risk Genes for Bipolar Disorder on Neural Function. . . .49Sophia Frangou

Symposium Comorbidity between Alcohol, Nicotine and Drug Dependence: Origins, Effects and TreatmentThursday, May 203:00 PM - 5:00 PMNottoway - 4th Floor

Chair: Mary-Anne Enoch

3:00 PMChildhood Trauma and Variation in GABAergic and Serotonergic Genes Predict Alcohol, Heroin and Cocaine Dependence. 50Mary-Anne Enoch

3:30 PMAssociation of Common Genetic Variants with Structural and Functional Brain Alterations in Alcohol and Nicotine Dependent Individuals.................................51Vibhuti Srivastava

4:00 PMNeuroimaging Effects of Comorbid Alcohol and Nicotine Dependence: Implications for Treatment.....................................................52Dieter J. Meyerhoff

4:30 PMNeurobiological Correlates of Stress and Drug Craving are Predictive of Addiction Relapse Outcomes.......................................53Rajita Sinha

Symposium Investigating Repetitive Transcranial Magnetic Stimulation (Rtms) with Functional Brain MeasuresThursday, May 203:00 PM - 5:00 PMMaurepas - 3rd Floor

Chair: F. Andrew KozelCo-Chair: Mark S. George

3:00 PM24

RTMS and PET: Prediction of Response and Effect of Treatment.......................................54Robert M. Post

3:30 PMTMS/fMRI: The Lessons we Have Learned about How to Better Treat Depression........55Ziad S. Nahas

4:00 PMGamma Oscillations in Response to Repetitive Transcranial Magnetic Stimulation in Healthy Subjects and Patients with Schizophrenia..............................................56Zafiris J. Daskalakis

4:30 PMUsing Functional Near Infrared Spectroscopy (fNIRS) to Measure Brain Changes Associated with rTMS..................................57F. Andrew Kozel

Symposium Automatic Emotion Control Circuitry: Dysregulations in Depression, Anxiety, Personality DisordersThursday, May 203:00 PM - 5:00 PMBayside A - 4th Floor

Chair: Harold W. KoenigsbergCo-Chair: Kevin Ochsner

3:00 PMExpectancy of Emotion and its Changes in Depression...................................................58Georg Northoff

3:30 PMSensitization and Habituation of Neural Networks in Response to Aversive Social Cues in Borderline and Avoidant Personality Disorder Patients.........................................59Harold W. Koenigsberg

4:00 PMAmygdala Habituation and Trait Anxiety in Adolescence.................................................60Todd Hare

4:30 PMMedial Prefrontal 5-HT2A Receptors Predict Temporal Habituation of Threat-Related Amygdala Reactivity....................................61Ahmad R. Hariri

Symposium

Human Studies of Oxytocin's Effects in SchizophreniaThursday, May 203:00 PM - 5:00 PMOak Alley - 4th Floor

Chair: David Feifel

3:00 PMRelationship of Neuroendocrine Dysfunction to Clinical Symptoms in Schizophrenia......62Morris Goldman

3:30 PMEndogenous Oxytocin Correlates with Improved Clinical Symptoms in Schizophrenia..............................................63Leah H. Rubin

4:00 PMIntranasal Oxytocin Added Adjunct to Antipsychotics Reduces Symptoms of Schizophrenia..............................................64Kai MacDonald

4:30 PMOxytocin Treatment of Social Cognitive Deficits, Paranoia and other Psychotic Symptoms in Schizophrenia........................65Cort A. Pedersen

Symposium microRNAs: Novel Modulators of Neuronal and Behavioral PlasticityThursday, May 203:00 PM - 5:00 PMGrand Ballroom ABC – 5th Floor

Chair: Husseini K. ManjiCo-Chair: Guang Chen

3:00 PMNon-Coding RNAs in Schizophrenia...........66Claes Wahlestedt

3:30 PMRapid Mechanisms of Molecular Tolerance......................................................67Andre Pietrzykowski

4:00 PMOpposite Effects of Chronic Exposure to Corticosterone and Antidepressants on miRNA Expression in the Hippocampus; Relevance to the Treatment of Mood Disorders......................................................68Peter Olausson

4:30 PM

25

Roles of Selected miRNAs in Stress Coping and Behavioral Regulation Related to Mania............................................................69Guang Chen

Symposium Neurosteroids as Novel Therapeutics in Schizophrenia and other CNS DisordersThursday, May 203:00 PM - 5:00 PMBorgne - 3rd Floor

Chair: Christine E MarxCo-Chair: E. Sherwood Brown

3:00 PMProof-of-Concept Randomized Controlled Trial with Pregnenolone in Mild Traumatic Brain Injury...................................................70Christine E. Marx

3:30 PMMulti-Year Continuation Study of Pregnenolone in Patients with Schizophrenia..............................................71Adam J. Savitz

4:00 PMPregnenolone for Mood and Cognition in Patients with Dual Diagnosis.......................72E. Sherwood Brown

4:30 PMAugmentation with Dehydroepiandrosterone (DHEA) in Treatment-Refractory Schizophrenia..............................................73Lars Fredrik Jarskog

Symposium Astrocytic Dysfunction and Major DepressionThursday, May 203:00 PM - 5:00 PMGrand Chenier - 5th Floor

Chair: Gustavo TureckiCo-Chair: Gerard Sanacora

3:00 PMFine Anatomical Features of White Matter Astrocytes in Depressed Suicides..............74Naguib Mechawar

3:30 PMAstrocytic Glutamate Clearance: Relationship to Stress-Related Pathophysiology and Mechanism of Antidepressant Action.................................75Gerard Sanacora

4:00 PMDysfunction of an Astrocytic Gene Network in Major Depression and Suicide................76Gustavo Turecki

4:30 PMUsing Magnetic Resonance Spectroscopy to Probe Glutamatergic Neurotransmission in Mood Disorders............................................77Dost Ongur

Symposium Enabling Medication Development for AddictionThursday, May 203:00 PM - 5:00 PMGrand Couteau - 5th Floor

Chair: Anne Cramer AndornCo-Chair: Curtis Wright

3:00 PMEnabling Medication Development: Translating from Preclinical to Clinical Imaging.........................................................78Linda J. Porrino

3:30 PMEnabling Medication Development: Defining Phenotypes through Clinical Imaging........79Anna Rose Childress

4:00 PMEnabling Medication Development: Optimizing Dosage Using Preclinical and Clinical Imaging...........................................80John David Beaver

4:30 PMEnabling Medicine Development: Use of the Human Laboratory for Preliminary Proof of Efficacy.........................................................81Stephanie S. O'Malley

Oral Session - Mood DisordersThursday, May 203:00 PM - 5:00 PMSouthdown - 4th Floor

Chair: See On-Line Program Book

3:00 PMNeurogenesis Dependent Modulations of Neuroplasticity in Cornu Ammonis Regions of the Adult Hippocampus...........................82Robert J. Schloesser

26

3:15 PMHighly Selective GSK3 Inhibition Modulates Affective Behaviors in Mouse......................83Tracey Petryshen

3:30 PMDrugs that Stimulate Oxytocin Release Promote Social Bonding in an Animal Model Relevant to Autism.......................................84Meera E. Modi

3:45 PMPrenatal Influenza Infection Alters Offspring Brain Development: Diffusion Tensor Imaging (DTI) Tractography of White Matter Pathways in the Rhesus Monkey................85Sarah J. Short

4:00 PMEpigenetic Regulation of Serotonin Transporter and Stress Adaptation in Humans and Non-Human Primates.............86Erin L Kinnally

4:15 PMComparison of Blood and Brain Transcriptome..............................................87Marquis P. Vawter

4:30 PMUnmedicated First-Episode Schizophrenia and Psychotic Bipolar Patients Show Reduced Neural Activation during Working Memory Maintenance...................................88James L. Reilly

4:45 PMLobar Volume Reductions and Psychotic Symptoms in People at High Genetic Risk of Schizophrenia..............................................89Stephen Lawrie

Poster SessionMixed TopicsThursday, May 205:00 PM - 6:30 PMGrand Ballroom DE – 5th Floor

Effects of Memantine and Donepezil on Object Recognition Memory and Hippocampal Acetylcholine Levels in Rats with Cholinergic Lesions.............................90Pradeep K. Banerjee

Acetylcholinesterase Inhibition Ameliorates Deficits in Motivational Drive and Apathetic Behavior.......................................................91

Keri MartinowichLongevity Gene Polymorphisms, Molecular Brain Aging Rates, and Promotion of Neurological Diseases.................................92Christin A. Glorioso

Selective Effects of Aging on Brain White Matter Microstructure...................................93Nikolai V. Malykhin

Structural Organization of the Frontal White Matter Pathways in the Adult and Aging Brain.............................................................94Nikolai V. Malykhin

Estrogen Receptor Beta 2 and the Effective Window for Estrogen Therapy.....................95Jun Ming Wang

The Effect of Single Prolonged Stress, a Rodent Model of Post Traumatic Stress Disorder, on Fear Conditioning, Extinction and Extinction Recall...................................96Sophie A. George

Alternative Splicing of Acetylcholinesterase: Relation to Stress-Iinduced Immobility and Anxiety in Different Mouse Strains..............97Ora Kofman

Estrogen and Progesterone Facilitate Recall of Fear Extinction in Rats............................98Mohammed Milad

Electroencephalography Changes by Deep Brain Stimulation on the Orbitofrontal Cortex in an Animal Model of Obsessive Compulsive Disorder........................................................99Sandra B. Raya Santoyo

The Effect of Electrical Stimulation in Orbitofrontal Cortex on Spontaneous Behavior in Rats.........................................100Sandra B. Raya Santoyo

Development of a Mouse Model to Identify the Molecular Underpinnings of Extreme Behavioral Inhibition..................................101Patrick H. Roseboom

PET Evaluation of Serotonin and Dopamine Transporter Occupancy Associated with Administration of SEP-225289...................102Christine DeLorenzo

27

Preliminary Results of Deep Brain Stimulation in the Inferior Thalamic Peduncle as a Tretament of Obsessive Compulsive Disorder......................................................103Fiacro Jiménez

Association between Initial Treatment Modality and Two-Year Outcome in Patients with Obsessive-Compulsive Disorder.......104Roseli G. Shavitt

Evidence for Unconscious, Perceptual Avoidance in Phobic Fear..........................105James L. Abelson

Exploring Cognitive Control in Working Memory in Obsessive Compulsive Disorder......................................................106Susanne E. Ahmari

Brain Correlates of Escape from Shock in Virtual Reality.............................................107Nicole E. Arkin

Left-Right Information Transmission Assessed from Bilateral Electrodermal Activity Reflects Level of Hypnotic Experience..................................................108Petr BobPretreatment Anterior Cingulate Activity Predicts Amygdala Attenuation in Social Phobic Placebo Responders.....................109Vanda Faria

Neurocircuitry Underlying Fear Reinstatement in Patients with Post Traumatic Stress Disorder......................................................110Sarah N. Garfinkel

Stress Facilitates the Acquisition of Well-Learned Operant Behavior in a Mouse Reversal Task.............................................111Carolyn Graybeal

fMRI of Amygdala Reactivity to Threat Faces at Varying Intensity in Social Phobia........112Heide Klumpp

The Temporal Course of Conditioned Fear-Generalization in Healthy Subjects...........113Allison Letkiewicz

Anxiety Modulates Hippocampal Activity during Virtual Navigation...........................114Cassie Overstreet

Electrophysiological Correlates of Attentional Processing in Obsessive-Compulsive Disorder......................................................115Angel D. Santana-Vargas

Friend or Foe? Neural Correlates of Reciprocity and Defection in the Trust Game in Social Phobia.........................................116Chandra Sekhar Sripada

Relation between Psychiatric Symptoms and Cortisol in the Process of Surgery Recovery.....................................................117Francisco J. Vaz-Leal

Role of BDNF val66Met Polymorphism on the Association Between Physical Activity and Incident Dementia......................................118Jae-Min Kim

Altered Cortical Development and Working Memory Deficits After Early Life Stress. . . .119Heather C. Brenhouse

Developmental Trajectories of Transcripts Regulating GABA Neurotransmission in Monkey Prefrontal Cortex..........................120Gil D. Hoftman Default Mode Network's Activity in Social Interaction : Increase or Decrease?...........121Sophie Guionnet

Event Related Coherence of Healthy Subjects upon Application of an Auditory Oddball Paradigm....................................................122Bahar Güntekin

Early Life Stress Due to Maltreatment in Childhood Modulates Reward Processing During an Inhibitory Control Task: An Antisaccade Study.....................................123Sven C. Mueller

Executive Attention Network Impairment Children with Chromosome 22q11.2 Deletion.......................................................124Joel Stoddard

Serotonergic Neurotransmission in ADHD: Availability of Tryptophan Influences Attentional Performance in Children and Adolescents................................................125Florian D. Zepf

Common Genetic Factors Influence Intelligence and Cortical Surface Area......126Anderson M. Winkler

28

Divergent Regulation of Pro-BDNF and Mature BDNF Expression during Development in Human Prefrontal Cortex.........................................................127Kayvon Salimi

Higher 5-HT(2A) Cortical Receptor Binding in Brains of Youth Suicide.............................128Hanga Galfalvy

An Initial Delineation of Growth Rates of the Corpus Callosum in Attention-Deficit/Hyperactivity Disorder. . .129Mary C. Gilliam

Genetic and Environmental Contributions to Neonatal Brain Structure: A Twin Study. . .130John H. Gilmore

Neuro-Functional Networks Supporting Cross-Sensory Emotion Processing in Teens with Autism Spectrum Disorder................131Geoffrey B. Hall

Neurocognition and Temperament in Depersonalization Disorder.......................132Heather A. Berlin

The Relationship between Amygdala Activation to Emotional Faces and Anxiety Symptoms in Adolescents with Autism Spectrum Disorders...................................133Johnna R. Swartz

Predicting the Effect of Methylphenidate Hydrochloride in Children with ADHD Using Multi-Channel NIRS....................................134Ayaka Takahashi

Brain Activities in Depressed Adolescents During a Working Memory Task: Pre- and Post-Fluoxetine Treatment........................135Rongrong Tao

Relationship between Novelty Change Detection and Autistic Traits in Adolescents with Autism.................................................136Gunes Yucel

Face Processing in the Broad Autism Phenotype: An fMRI Study.........................137Gunes Yucel

Association of Cortisol Stress Response with Depression and Anxiety Symptoms in Adolescents with Diabetes........................138Daphne J. Korczak

Grey Matter Volume Correlates with Performance in a Virtual Water Maze Task:

A Study of Boys with Androgen Excess. . .139Sven C. Mueller

Increased Cortical Excitability after High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in Adolescents with Treatment-Resistant Major Depressive Disorder (MDD)...........................................140Paul E. Croarkin

Acute Nicotine Effects on Response Inhibition: An fMRI Study of the Stop Signal Task............................................................141Alexandra S. Potter

Face Processing in Depersonalization Disorder: An fMRI Study of Emotion and Familiarity...................................................142Sarah Ketay

Emotion Regulation of Affective Stimuli in Depersonalization Disorder: Psychophysiological and Subjective Findings......................................................143Sarah Ketay

Preliminary Evidence for Cannabinoid Receptor CB1 Polymorphisms in Cannabis-Induced Chronic Depersonalization..........144Kai Monde

Temporo-Parietal Junction Stimulation in the Treatment of Depersonalization Disorder. 145Antonio Mantovani

Contrasts in Taste Reward Expectation vs. Unexpected Receipt in Bulimia Nervosa...146Michael D. Rollin

Taste Challenge with a High Fat Stimulus Reveals Altered Striatal Response in Anorexia And Bulimia Nervosa after Recovery.....................................................147Angela Wagner

The Impact of the Anti-Obesity Drug on Brain Responses to Food Images in the Fasted and Fed States...................................................148Victoria C. Cambridge

Differentiating the Attention Abnormalities Undermining Affect Regulation in Psychopathy and Externalizing Disorders....................................................149Arielle R. Baskin-Sommers

Exaggerated Amphetamine-Induced Dopamine Release in Striatal and

29

Extrastriatal Regions Predicts Attentional Dyscontrol in Healthy Individuals.............150Joshua W. Buckholtz

A Common, Population-Specific Stop Codon in HTR2B Co-Segregates with Severe Impulsivity..................................................151Laura Bevilacqua

Evidence of Association between the Leptin Receptor (lepr) Single Nucleotide Polymorphism (snp) Rs3806318 and Suicide Attempts in Females..................................152Hilario Blasco-Fontecilla

Increased Brainstem 5-HT Reuptake Transporters (SERT) in Males with Extreme Levels of Impulsive Aggression: A PET Study Using 11C-DASB..............................153Angela J. Rylands

Relationship between DTI White Matter Abnormalities and Impulsivity in OIF/OEF Combat Veterans with Blast-Related Mild TBI.......................................................154Rachel N. Shiovitz

Genetic Vulnerability to Inflammation-Related Major Depressive Disorder is Influenced by Age..............................................................155Francis E. Lotrich

Regional Urocortin 1 Response to Chronic Social Defeat and Desipramine Treatment....................................................156Garth Bissette

5-HTTLPR Genotype, Chronic Fluoxetine Administration, and Cortical TREK1 Protein Expression in Rhesus Monkeys................157Ryan Bogdan

17b Estradiol Decreases the Stress Induced Acquisition of Learned Helplessness in Female Rats................................................158Teruko M. Bredemann

Possible Involvement of Bax Inhibitor 1 (BI-1), A Modulator for Endoplasmic Reticulum (ER) Cellular Stress, in Affective Resilience....................................................................159Joshua Hunsberger

Activation of ERK1/2 and Akt Signal Pathways in the Brain of Ouabain Rat Model for Mania.....................................................160Se Hyun Kim

Role of the NMDA Receptor NR2B Subunit in Mediating Anxiety- and Depression-Like Behaviors....................................................161Carly L Kiselycznyk

Characterization of the Ankyrin 3 Bipolar Disorder Risk Gene in Mice.......................162Melanie P. Leussis

Omega-3 Fatty Acid Deficiency Increases Plasma Proinflammatory Cytokine Levels in Rats: Normalization with Omega-3 Fatty Acid Supplementation........................................163Robert K. McNamara

Perinatal Omega-3 Fatty Acid Deficiency Alters Regional Brain Activity in Adult Rats: An in Vivo Magnetic Resonance Imaging Study...........................................................164Robert K. McNamara

Effects of Housing Conditions in the Reduction of Submissive Behavior Model of Antidepressant Activity..............................165Kurt Rasmussen

Increasing Adult Hippocampal Neurogenesis is Sufficient to Enhance Cognition but not Mood...........................................................166Amar Sahay

Chromatin Modification in Psychiatric Disease: Histone Deacetylase Inhibitors Differentially Affect Acetylation and Behavior in Mouse Models........................................167Frederick A. Schroeder

Magnetic Resonance Imaging of Whole, Anterior and Posterior Hippocampal Volumes in Behaviorally Depressed Cynomolgus Macaques....................................................168Stephanie L. Willard

Expression Levels of NF-kappaB p65 and Sirtuin6 in Prefrontal Cortex Area 10 of subjects with Major Depressive Disorder. 169Heidi S. Fitzgibbon

Synaptosomal Cholesterol and Phospholipid Characterisation in Suicide Completers. . .170Erika B. Freemantle

Reduced Glutathione Levels in Post-Mortem Prefrontal Cortex from Mood Disorder Patients.......................................................171Jeremy W. Gawryluk

30

Levels of Several ERK Pathway Proteins and PDE4 are Altered in Postmortem Frontal Cortex of Individuals with Mood Disorders....................................................172Xavier Guitart

An In-Vitro Model System to Study rTMS Effects on Cell Signaling...........................173Julian Hellmann

Chronic Fluoxetine Treatment Differentially Regulates Freud-1 and Nudr in the Rat Prefrontal Cortex........................................174Abiye H. Iyo

Differential Glucocorticoid Receptor Expression in the Brain of Suicide Completers with a History of Childhood Abuse..........................................................175Benoit Labonté

Fluoxetine Treatment Does Not Alter Density or Size of CNPase-Immunoreactive Oligodendrocytes in Prefrontal White Matter in Rhesus Monkeys....................................176Beata Legutko

Gene Expression of Estrogen Receptor α and; and Serotonin Transporter in Women with Premenstrual Syndrome and Premenstrual Dysphoric Disorder.............177Sonali Lokuge

Functional Analysis of microRNA Expression Profiles in Brain Tissue from Suicide Completers.................................................178Gilles Maussion

Adolescents with Major Depressive Disorder Exhibit Selective Deficits in Erythrocyte Docosahexaenoic Acid Composition: Dissociation from Antidepressant Medication Effects.........................................................179Robert K. McNamara

Blood Vessel Pathology and Alterations in Gene Expression of Angiogenic Factors in the Orbitofrontal Cortex in Major Depression.................................................180Grazyna Rajkowska

Volume, Number of Neurons, and Number of Glia in the Basolateral Amygdala in Major Depressive Disorder: A Postmortem Stereological Study....................................181Marisa J. Rubinow

Astrocytic Alterations in Postmortem Hippocampus in Major Depressive Disorder (MDD)..........................................................182Craig A. Stockmeier

Tumor Necrosis Factor-alpha Enhanced AMPA-Containing Synaptogenesis In The Central Nervous System............................183Cristina Wheeler-Castillo

Daily Left Prefrontal TMS for Major Depression: A Sham-Controlled Multi-Site Randomized Trial (NIH Optimization of TMS for Depression Study, OPT-TMS)..............184David H. Avery

Randomized Trial of Unilateral and Bilateral Prefrontal Cortex Transcranial Magnetic Stimulation in Treatment Resistant Major Depression.................................................185Kate Hoy

Innovative Depression Treatments: Magnetic Seizure Therapy.........................................186Kate E. Hoy

Seizure Expression of Magnetic Seizure Therapy in Depression...............................187Sarah Kayser

Complementary Use of Tai Chi Improves Resilience, Quality of Life, and Cognitive Function in Depressed Older Adults.........188Helen Lavretsky

Early Effects of Electroconvulsive Therapy (ECT) on Sleep Architecture in Major Depression.................................................189Daniel F. Maixner

Deep Brain Stimulation (DBS) of the Subgenual Cingulate Gyrus for Treatment Resistant Depression (TRD)......................190Angela Merkl

Relationships of Pre and Postpartum Biological Variables with Depression and Anxiety History and Symptoms, Trauma History and Stressful Life Events: Preliminary Results....................................191Cort A. Pedersen

Preliminary Result of the Maintenance Phase of an Open Pilot Trial on rTMS Treatment of Bipolar Depression....................................192Guohua Xia

31

Face Emotion in Adult Bipolar and Unipolar Depression and Controls...........................193Jacqueline C. Baumann

Abnormal Temporal Sychronization in Bipolar Disorder as Measured by a Paced Finger Tapping Task..............................................194Amanda R. Bolbecker

Effect of Depression on Gender-Sensitive Cognitive Performance..............................195Emily M. Briceno

Social Reasoning Deficits in Subsyndromal Patients with Major Depressive Disorder. .196Andree M. Cusi

Cardiovascular Autonomic Nervous System Alterations during Emotion Regulation in Subjects at Risk for Psychopathology......197Martina Di Simplicio

Older Suicide Attempters Bet on Unlikely Gambles......................................................198Alexandre Y. Dombrovski

Older Suicide Attempters Fail to Represent Choice Consequences: Computational Model-Based fMRI Study...........................199Alexandre Y. Dombrovski

Volume of Right Precuneus is Associated with Visual Perspective in Autobiographical Memory: A Voxel-Based Morphometry Study...........................................................200Philippe Fossati

Self-Referential Processing and the Prefrontal Cortex Over the Course of Depression: A Pilot Study.........................201Philippe Fossati

Regulatory Focus and Reward Sensitivity: Integrating Social-Cognitive and Affective Neuroscience Perspectives.......................202Elena L. Goetz

Bipolar and Unipolar Depression are Distinguished by Patterns of Abnormal Occipital Activity to Happy and Sad Facial Expressions................................................203Stefanie Hassel

Comparison between Depressed Patients and Healthy Controls in Error Refractory Period Using the Parametric Go/No-Go Test........204Kathleen E. Hazlett

Positive Emotional Expression and the Self-Other Boundary in Bipolar Disorder.........205Matthew T. Keener

Autobiographical Memory and Future-Oriented Thinking in Recurrent Major Depressive Disorder...................................206Matthew J. King

Reduced Lateral Prefrontal Cortex Activation During an Emotional Working Memory Task in Pediatric Bipolar Disorder.....................207Cecile D. Ladouceur

Regional Brain Asymmetries during Verbal and Spatial Tasks in Depression with High or Low Trait Anxiety.......................................208Carlye B. Manna

Obsessive Compulsive Disorder and Executive Cognitive Functions: Correlation to a 18FDG-PET Study...............................209Bruno Millet

Are Neurocognitive Complaints Persistent During the Follicular Phase in Women with Premenstrual Syndrome and Premenstrual Dysphoric Disorder?..................................210Brianne Nicholls

Significant Reduction of EEG Alpha Activity and Sensory Alpha Response in Bipolar Patients.......................................................211Ayşegül Özerdem

Decrease of Long Distance Gamma (28-48 Hz) Coherence in Euthymic Drug Free Bipolar Patients upon Cognitive Load......212Ayşegül Özerdem

Cognitive, Emotion, and Motor Inhibition in Bipolar Disorder.........................................213Jo Cara Pendergrass

Stress, Limbic Irritability and Nonlinear Heart Rate Dynamics in Unipolar Depressive Patients.......................................................214Jiri Raboch

Traumatic Stress, Dissociation and Limbic Irritability in Patients with Unipolar Depression.................................................215Jiri Raboch

APOE Genotype and Bipolar Disorder Cognition....................................................216Marcio G. Soeiro de Souza

COMT Val158Met and Neurocognitive Function in Bipolar Disorder.....................217

32

Marcio G. Soeiro de Souza

Conflict Monitoring Dysfunction Underlying the Negative Attentional Bias in Remitted Depressed Patients....................................218Marie-Anne Vanderhasselt

Visual Affect Recognition Accuracy Differences by Psychiatric Illness.............219Aaron C. Vederman

Biochemical Changes in Neurotensin Receptor Null Mice: Relevance to Schizophrenia............................................220Mona M. Boules

Differential Protein Expression of Risperidone and Paliperidone in Rat Pre-Frontal Cortex: A Dose Response Comparison..................221Maria Corena -McLeod

Glutamate-Dopamine Interactions in a Maternal Immune Activation Model with Relevance to Schizophrenia......................222Stefanie L. Bronson

Metabolic Alterations in the Cortex of a Mouse Model with Glutathione Deficit - Relevance to Schizophrenia......................223Kim Q. Do

Human Endogenous Retrovirus in Schizophrenia: A New Avenue of Research at the Gene-Environment Interface................224Nora Hamdani

Assessing Mechanisms of Reduced Cannabinoid 1 Receptor (CB1R) Expression in Schizophrenia: Contribution of Reduced GAD67 mRNA Expression..........................225Stephen M. Eggan

Adult-Onset Glutamate Receptor Expression Deficits in the Hippocampus of Glutaminase-Deficient Mice.............................................226Inna Gaisler-Salomon

Attenuation of Phencyclidine (pcp)-Induced Novel Object Recognition (nor) Deficit by the Combination of the Atypical Antipsychotic Drugs (apd), Clozapine or Lurasidone, with Metabotropic Glutamate Receptor (mglur) 2/3 Agonist, Ly379268......................................227Masakuni Horiguchi

Hippocampal Oscillations in the Rodent Model of Schizophrenia Induced by Amygdale Gaba Receptor Blockade..........228

Bernat Kocsis

Effects of Disc1 Truncation and Levodopa Metabolism on Mouse Open Field and Circadian Wheel-Running Behavior..........229Lisa Krug

Involvement of Neurotensin Receptor Subtype 1 in the Neuronal Mechanisms of Acute and Chronic Phencyclidine-Induced Schizophrenia-Like Signs: Behavioral, Neurotransmitter, and Molecular Studies. 230Zhimin Li

Vesicular Monoamine Transporter 1 (VMAT1) Knock-Out Mice Display a Hyper-Dopaminergic Phenotype - Implications for Psychotic Disorders...................................231Falk W. Lohoff

Effects of Pramipexole on Sensorimotor Gating and cAMP/PKA Signaling in the Nucleus Accumbens..................................232Neal R. Swerdlow

Pramipexole Infusion into the Nucleus Accumbens Disrupts Prepulse Inhibition in Rats.............................................................233Martin Weber

The Effects of the Dopamine D2 Agonist Sumanirole on Prepulse Inhibition in Rats.............................................................234Martin Weber

Elevated SHMT1 Level Leads to Lowed Glycine Availability and Reduced Prepulse Inhibition in Mice and is Associated with Schizophrenia: A New Molecule Relevant to NMDA Theory of Schizophrenia................235Takeo Yoshikawa

Myelin-Associated Proteins in Prefrontal Grey and White Matter in Schizophrenia and Bipolar Disorder.........................................236Clare L. Beasley

GAD67 Protein Levels in the Dorsolateral Prefrontal Cortex of Subjects with Schizophrenia............................................237Allison A. Curley

GABAA alpha1 Subunit mRNA Expression in Pyramidal Cells and Interneurons in the

33

Dorsolateral Prefrontal Cortex of Schizophrenia Subjects.............................238Jill R. Glausier

An Inverse Relationship between Cortisol and BDNF Levels in Schizophrenia: Data from Human Postmortem and Animal Studies....................................................................239Anilkumar Pillai

Rapid Tranquillisation for Agitated Patients in Emergency Psychiatric Rooms: A Randomised Trial of Olanzapine, Ziprasidone, Haloperidol Plus Promethazine, Haloperidol Plus Midazolam and Haloperidol....................................................................240Leonardo Baldaçara

Differential Impact of Oral and Long-Acting Risperidone Formulations on Brain Myelination of Adult Schizophrenia Patients.......................................................241George Bartzokis

Differential Effects of Dextro-Amphetamine Administration in Schizophrenia vs. Healthy Control Subjects........................................242Raymond Y. Cho

The Heterogeneity of Antipsychotic Response in the Treatment of Schizophrenia....................................................................243Robert Conley

Analysis of Gene Variants Associated with Iloperidone Response in Patients with Schizophrenia Who are Treated with Risperidone or Olanzapine........................244Bonnie Fijal

Efficacy and Safety of Long-Acting Injectable Paliperidone Palmitate Relative to Long-Acting Haloperidol, Bromperidol and Fluphenazine Decanoate for Long-Term Treatment in Patients with Schizophrenia Using Number Needed to Treat and Number Needed to Harm..........................................245Srihari Gopal

The Power of Sham rTMS on Chronic Hallucinated Voices in Schizophrenia Patients: An fMRI-Guided rTMS Randomized, Double-Blind, Sham-Controlled Study......246Marie-Laure Paillère Martinot

A Randomized, Double-Blind, Study of Flexible Doses of Paliperidone Palmitate and

Risperidone Long-Acting Therapy in Patients with Schizophrenia....................................247Gahan Pandina

Verbal Working Memory in Cognitive and Symptom Subtypes of Schizophrenia.......248Daniel M. Alschuler

Associative Inference is Impaired in Schizophrenia............................................249Kristan Armstrong

Adolescent-Onset Psychosis and Disrupted Neurocognitive Development: A Cross-Sectional Study of Neuropsychological Performance...............................................250Peter Bachman

Functional MRI and Dynamic Causal Modeling Reveal Inefficient and Imbalanced Network Interactions in Developmentally Vulnerable Adolescents.............................251Neil Bakshi

The Backward Masking Red Light Effect in Schizophrenia: Relationship with Symptoms and Premorbid Intelligence Estimate........252Jeffrey S. Bedwell

Effect of Comt Val108/158Met Genotype on Different Executive Functions in Patients with Schizophrenia....................................253Arthur A. Berberian

Modeling Cognitive Phenotypes from Circuit to Syndrome...............................................254Robert M. Bilder

Dissociative Symptoms and Interregional EEG Cross-Correlations in Paranoid Schizophrenia............................................255Petr Bob

Psychopathological Symptoms and Neurocognitive Tets Performance in Polish 1200 Schizophrenic Patients Treated with Olanzapine (Olzapin)..................................256Alina Borkowska

Cannabis Use is Associated with Greater Prepulse Inhibition in Normals, Prodromal and First Episode Psychosis Patients......257Kristin Cadenhead

Impact of Neurocognition on Social and Role Functioning in the Prodromal Phase of Schizophrenia............................................258Ricardo E. Carrion

34

COMT Influences on Prefrontal and Striatal Bold Responses During Working Memory Among Individuals with Schizophrenia, Their Siblings and Healthy Controls...................259Alan E. Ceaser

Stability, Diagnostic Specificity and Genetic Liability for Context-Processing Deficits In Schizophrenia............................................260Raymond Cho

Intra-Individual Variability Across Neuropsychological Tasks in Schizophrenia: Its Relationship to Disease Status and Functioning................................................261Veronica T. Cole

Abnormal Early and Late Selective Attention Related ERPs in Subjects at Familial Risk for Schizophrenia............................................262Franc C. Donkers

Interhemispheric Integration in Schizophrenic and Bipolar Patients: A Study with the Redundant Signal Effect..............263Vincenzo Florio

Cerebellar Timing Dysfunction in Schizotypal Personality Disorder: Eyeblink Conditioning as a Potential Biomarker for Schizophrenia............................................264Jennifer K. Forsyth

No Influence of Age at Onset and Duration of Illness on Executive Functioning Among Patients with Schizophrenia......................265Ary Gadelha

Attentional Load and Visual Gamma Oscillations in Schizophrenia....................266Shahab Ghorashi

Relationship between Steady-State Gamma Driving and Cognitively Elicited Gamma Frequency Responses in Schizophrenia. .267Mei-Hua Hall

Emotional Interference Effects during Voluntary Attention in Individuals with Schizophrenia and Familial High Risk......268Sarah J. Hart

The Course of Neuropsychological Performance and Functional Capacity in Older Patients with Schizophrenia: Influences of Previous History of Long-Term Institutional Stay........................................269

Philip D. Harvey

Impairment of Executive and Storage Aspects of Spatial Working Memory in Patients with Schizophrenia and Their First-Degree Relatives.....................................................270Rachel G. Higier

Cortical Inhibition and Working Memory in Schizophrenia: A TMS/EEG Study............271Kate Hoy

Differences in Frontal Activation in Adult Patients with Schizophrenia and in Psychotic Adolescents with Schizophrenic Symptoms in Two fMRI Tasks......................................272Laure Jaugey

Generalized Enhancement of Episodic Memory by Prior Reward Experience........273Elizabeth B. Johnson

Attention Modulation of Sensory Processing: An fMRI Study............................................274Sarah K. Keedy

Emotion Processing Impairment in Youths At-Risk for Psychosis................................275Christian G. Kohler

Schizophrenia-Like Cognitive Control Deficits in First Episode Bipolar Disorder with Psychotic Features............................276Tyler A. Lesh

Automatic Semantic Activation in Schizophrenia: A Masked Priming Study. 277Maya Libben

Strategies for Enhancing Episodic Memory in Schizophrenia............................................278Laura A. Libby

Memory and Response Conflict in Schizophrenic Patients and Normal Controls......................................................279Toni Mahowald

Performance Based Assessment of Functional Skills in Severe Mental Illness: Results of a Large-scale Study in China...280Belinda J. McIntosh

Dose-Response Effects of Single-Dose Modafinil on Cognition in Schizophrenia. 281Michael Minzenberg

Chronic Methamphetamine Administration Causes Differential Regulation of

35

Dopaminergic Transcription Factors in the Rat Ventral Midbrain..................................282Jean Lud Cadet

Epigenetics of Fetal Alcohol Syndrome....283Kornel E. Schuebel

Translational Development of Novel Pharmacotherapeutic Strategies for Psychostimulant Dependence...................284Steven T. Szabo

The Role of Acetaldehyde in Human Psychomotor Function: A Double-Blind Placebo-Controlled Crossover Study........285Kyung-Yeol Bae

Cognitive Functions and Affective Disorders in Chronic Hepatitis C Patients during Treatment with Interferon-Alpha plus Ribavirin.....................................................286Wiktor Drozdz

Cannabis Use Before Age 15 is Associated with Poorer Executive Functioning...........287Maria Alice Fontes

Memory Functioning in Abstinent Chronic Cannabis Users is Associated with Age of Onset and Years of Daily Consumption....288Maria Alice Fontes

Characteristics of College Freshmen who Abstain from Alcohol Consumption..........289Meredith K. Ginley

Dysfunctional Reward Processing in Current Cocaine Abusers during an Interpersonal Competitive Game......................................290Christopher J. Hyatt

Validation of the Kreek-McHugh-Schluger-Kellogg (KMSK) Scale of Substance Use in an Urban Low-Income and Predominantly African-American Sample of Primary Care Patients.......................................................291Yilang Tang

Functional Genetic Variants that Increase Synaptic Serotonin and 5-HT3 Receptor Sensitivity Additively Predict Alcohol and Drug Dependence.......................................292Mary-Anne Enoch

Analyses of Association of the Serotonin Transporter Gene (Slc6a4) Variants with Alcohol Withdrawal Seizures (aws) and/or Delirium Tremens (dt)................................293Victor M. Karpyak

Oxytocin as a Novel Treatment for Drug Dependence: From the Bench, to the Street, to the Clinic................................................294Dean S. Carson

Ethical Issues in Translational Research in Psychiatry ..................................................295David Brendel

The Role of Arginine Vasopressin in Human Social Cognition.........................................296Gail A. Alvares

Late-Breaking Posters - ClinicalThursday, May 205:00 PM – 6:30 PMGrand Ballroom DE

At the time of publication, these abstracts were not available to include in the program book. Please see the On-Line Program Planner at www.sobp.org to view the abstract.

A Randomized Clinical Trial of Weight Loss Treatment in Schizophrenia, Compared to an Active Control Condition, and Treatment as Usual ..........................................................297Rohan Ganguli

Association of Seropositivity for Influenza and Coronaviruses with Mood Disorders and Suicidal Behavior ......................................298Olaoluwa O. Okusaga

Serotonin Dysfunction linked to Cognitive Vulnerability in Individuals at High Familial Risk for Depression ...................................299Adriana Feder

Metformin in the Treatment of Antipsychotic-induced Weight Gain In Schizophrenia . . .300L. Fredrik Jarskog

Atomoxetine for the Treatment of ADHD in Young Adults with an Assessment of Associated Functional Outcomes ............301Todd Durell

Does SANS Make Sense? A Call for Revision of the Factor Structure of Negative

36

Symptoms of Schizophrenia in the Scale for the Assessment of Negative Symptoms (SANS) .......................................................302Liron Rabany

Temporal Regions Are Disconnected In Psychosis ..................................................303Jack R. Foucher

Effect of Cannabinoids on Opiate Withdrawal: Findings from Preclinical and Clinical Studies .........................................304Jillian L. Scavone

Initial Efficacy Results from the Feasibility Study of Multi-site Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) .....................................................305Richard Keefe

A Multisite Placebo Controlled Trial of Morning or Evening Dosed Extended-Release Guanfacine in Combination with Psychostimulants in Children and Adolescents with ADHD ............................306Timothy E. Wilens

Depression Scores After One Hour Of Bright Light Versus Dim Red Light In Patients With Seasonal Affective Disorder .....................307Gagan V. Nijjar

Neurocognitive Effects of Lithium and Valproate in Bipolar Suicide Attempters . .308Patricio Molero

A Randomized, Double-Blind, Parallel-Group, Fixed Dose, Clinical Trial of Quetiapine 600 mg/day vs 1200 mg/day for Patients With Treatment-Resistant Schizophrenia or Schizoaffective Disorder ...........................309Jean-Pierre Lindenmayer

Executive Dysfunctions Develop With Stimulant Use - Evidence from a Non-Dependent Cohort .....................................310Martina Reske

Rapid Beneficial Effects of Olanzapine on Metacognition of Healthy Subjects ..........311J. Bruno Debruille

Applying a Clinical Staging Framework in Young People Who Present With Anxiety, Depressive or Psychotic Syndromes .......312Anna E. Sidis

Co-morbidity of the Familial Forms of Mood Disorders with Chronic Medical Disorders ...................................................313

Tuong-Vi Nguyen

Major Depression Effects on Sexual Function and Treatment with Gepirone-ER - Why Hyposexual Desire Disorder (HSSD) and Female Sexual Arousal Disorder (FSAD) Should Not be Combined in DSM-V .........314Louis F. Fabre

Remission of Psychotic Depression in the STOP-PD Study: Impact of Prior Pharmacotherapy ......................................315Daniel M. Blumberger

Withdrawn..................................................316

The Side Effects of Mirtazapine Augmentation in Schizophrenic Patients Treated With Risperidone: A Preliminary Randomized Controlled Trial ....................317Sung Joon Cho

Withdrawn..................................................318

The Evaluation of Salivary Glands Function among Patients with Schizophrenia with Clozapine-induced Hypersalivation .........319Chia-chun Hung

The C-RAT: A Comprehensive Risk Assessment Tool for Use before Prescribing Psychotropics ...........................................320Cletus Carvalho

Left Intentionally Blank.......................321-323

2011 Program Planning MeetingThursday, May 207:00 PM – 9:00 PMGallier AB – 4th Floor(by invitation)

37

FRIDAY, May 20

Continental BreakfastFriday, May 217:00 AM – 8:00 AMGrand Ballroom Foyer – 5th Floor

RegistrationFriday, May 217:00 AM – 5:00 PMGrand Ballroom Foyer – 5th Floor

Speaker-Ready RoomFriday, May 217:30 AM – 5:00 PMEdgewood AB – 4th Floor

Plenary Session – AddictionFriday, May 218:00 AM – 10:15 AMGrand Ballroom ABC – 5th Floor

Chair: J. John Mann, MD

8:00 AMThe Genomics of Addiction.......................324David Goldman, MDNIH/NIAAA

8:45 AMPharmacological and Genetic Modulation of Motivated Decision Making in Corticostriatal Circuits.......................................................325Michael J. Frank, PhDBrown University

9:30 AMA Genomic Approach to the Treatment of Alcoholism.................................................326Charles P. O’Brien, MDUniversity of Pennsylvania

BreakFriday, May 2110:15 AM -10:30 AMGrand Ballroom Foyer – 5th FloorAbbreviated, please return promptly

Award PresentationsFriday, May 2110:30 AM -10:50 AMGrand Ballroom ABC – 5th Floor

Presidential LectureFriday, May 2110:50-11:50Grand Ballroom ABC

Chair: J. John Mann, MD

Addiction: Conflict Between Brain Circuits.......................................................327Nora D. Volkow, MDNIH/NIDA

Lunch/NetworkingFriday, May 21, 201011:50 AM – 12:30 PMGrand Ballroom Foyer – 5th Floor

Box lunches will be available for all registered attendees.

Business MeetingFriday, May 21, 201012:00 PM – 12:30 PMRhythms 3 – 2nd Floor

All members are encouraged to attend and non-members are invited.

Symposium Principles of Methamphetamine Addiction: From Basic Neuroscience to Clinical PsychopharmacologyFriday, May 2112:30 PM - 2:30 PMOak Alley - 4th Floor

Chair: Jean Lud Cadet

12:30 PMMolecular and Neurobiological Mechanisms of Methamphetamine Abuse......................328Jean Lud Cadet

1:00 PMPET Imaging of Methamphetamine Distribution and Kinetics in Humans........329Joanna S. Fowler

1:30 PMMethamphetamine Self-Administration in Rats as a Model for Persistent Neuroadaptations in the Brains of Chronic Methamphetamine Abusers......................................................330Irina N. Krasnova

2:00 PM38

Developing Pharmacotherapies for Methamphetamine Addiction.....................331John E. Mendelson

Symposium Genetic, Epigenetic, and Molecular Aspects of GABA FunctionFriday, May 2112:30 PM - 2:30 PMBorgne - 3rd Floor

Chair: Alessandro GuidottiCo-Chair: Daniel Weinberger

12:30 PMCircuit-specific Alterations in the Strength, Kinetics and Nature of Cortical GABA Neurotransmission in Schizophrenia........332David Lewis

1:00 PMGenetic Regulation of GABA Activity and Risk for Schizophrenia...............................333Daniel Weinberger

1:30 PMFunctional Analysis of the Human GAD1 Promoter.....................................................334Dennis R. Grayson

2:00 PMMolecular Determinants of Dysregulated GABAergic Gene Expression in the Prefrontal Cortex of Subjects with Schizophrenia............................................335Schahram Akbarian

Symposium New Perspectives on Dopamine and Reward Mechanisms in PsychopathologyFriday, May 2112:30 PM - 2:30 PMBayside BC - 4th Floor

Chair: Larry J SieverCo-Chair: Anissa Abi-Dargham

12:30 PMDopamine’s Role in ADHD Symptoms: Beyond an Attention Deficit.......................336Nora D. Volkow

1:00 PMAnorexia Nervosa: Neural Circuit Bias towards Delayed Gratification, Inhibition, and Over-Concern with Consequences?.........337Walter H. Kaye

1:30 PMDopamine Release and D1 Binding in the Schizophrenia Spectrum...........................338Larry J. Siever

2:00 PMSex Differences in Alcohol Induced Dopamine Release in Young Adults: A PET Imaging Study...........................................................339Anissa Abi-Dargham

Symposium Toward Individualized Treatment for Depression: From Neurophysiology to Clinical PracticeFriday, May 21 12:30 PM - 2:30 PMMaurepas - 3rd Floor

Chair: Gerard E BruderCo-Chair: Jonathan W. Stewart

12:30 PMAssessment of Monoamine Transmission in Animals to Identify Superior Antidepressant Strategies....................................................340Pierre Blier

1:00 PMAuditory Evoked Potential (AEP) and EEG Measures in Depressed Patients Predict Response to Antidepressants...................341Craig E. Tenke

1:30 PMQuantitative EEG Measures of Frontal Activity as Biomarkers for Predicting Treatment Outcomes in Major Depression342Ian A. Cook

2:00 PMInitial Exploration of an fMRI-Based Algorithm for Selecting Patients into Treatment with Cognitive Behavior Therapy (CBT) and Antidepressants........................343Greg J Siegle

Symposium Mouse models of neuregulin signalling and their relevance to schizophreniaFriday, May 2112:30 PM - 2:30 PMGrand Chenier - 5th Floor

Chair: Amanda J LawCo-Chair: Paul J Harrison

39

12:30 PMPhysiological, Neurochemical and Behavioral Analyses of the Neuregulin Signaling Pathway in Wild-Type and Mutant Mice: Implications for Schizophrenia.................344Andres Buonanno

1:00 PMNeuregulin Signaling in Cortico-Limbic Circuits Compromised in Schizophrenia. .345Lorna W. Role

1:30 PMTm-Domain Neuregulin-1 Mutants: Ethological, Social, Cognitive and Neurological Phenotypes in Relation to Schizophrenia............................................346John L. Waddington

2:00 PMThe Hippocampal Phenotype of Transgenic Neuregulin 1 Type I Over-Expressing Mice.............................................................347Paul J. Harrison

Symposium Affective and Cognitive Modulation of Pain Processing in Psychiatric DisordersFriday, May 2112:30 PM - 2:30 PMNottoway - 4th Floor

Chair: Karl J BärCo-Chair: Jon-Kar Zubieta

12:30 PMInfluence of Anticipation on Pain Processing in Patients with Borderline Personality Disorder......................................................348Christian Schmahl

1:00 PMEndogenous Opioid System at the Interface of Emotion and Pain Regulatory Mechanisms................................................349Jon-Kar Zubieta

1:30 PMAltered Functional Brain Response during Anticipation and Processing of Heat Pain in Major Depressive Disorder (MDD).............350Irina A. Strigo

2:00 PMThe Influence of Mood Induction on Pain Perception in Helathy Subjects and Controls......................................................351Karl J. BärSymposium

Abnormalities in Reward-Related Neural Circuitry in Mood DisordersFriday, May 2112:30 PM - 2:30 PMGrand Ballroom ABC

Chair: Mary Louise PhillipsCo-Chair: Diego A Pizzagalli

12:30 PMMajor Depression and Variation in TREK1 Gene are Associated with Blunted Striatal Responses to Rewards..............................352Diego A. Pizzagalli

1:00 PMDiminished Dopamine Release in Response to Unpredicted Monetary Reward in Major Depressive Disorder...................................353Wayne C. Drevets

1:30 PMReward Function in Adolescent Depression: Brain, Behavior, Mood, and Treatment Response....................................................354Erika E. Forbes

2:00 PMIncreased Striatal Activation during Reward Anticipation in Euthymic Bipolar Adults. .355Robin Nusslock

Symposium Pharmacogenetics Imaging: a method to understand in-vivo genetic regulatory effectsFriday, May 2112:30 PM - 2:30 PMBayside A - 4th Floor

Chair: Gonzalo Laje

12:30 PMIs Serotonin Transporter Expression Regulated by the Same HTR2A Variants Associated with Citalopram Response?.. .356Gonzalo Laje

1:00 PMMolecular Imaging of the 5-HT System: Behavioral and Genetic Influences...........357Gitte Moos Knudsen

1:30 PMEpistasis in Brain Imaging with Akt1 and Pharmacogenetics of Cognition in Schizophrenia............................................358Hao-Yang Tan2:00 PM

40

Neuroimaging and Genetics of Antidepressant Response.........................359Francesco Benedetti

Late Breaking Oral Session - ClinicalFriday, May 2112:30 PM - 2:30 PMGrand Couteau - 5th Floor

Glycine Transporter Inhibition Attenuates the Psychotomimetic Effects of Ketamine in Healthy Humans Subjects .........................360Deepak Cyril D'Souza

Eye-Movements Reveal Disrupted Relational Memory in Schizophrenia .........................361Lisa E. Williams

A Disrupted Affective Pathway in Adolescent Schizophrenia Offspring: Direct Evidence of Disordered Frontal Modulation of the Amygdala using fMRI and Dynamic Causal Modeling ....................................................362Sunali Wadehra

Gene Expression In Lithium-treated Mice and Knockout Mice With Lithium-like Behavior ....................................................363Galila Agam

Prefrontal N-Acetylaspartate Concentrations in Manic Bipolar Patients Associated with Treatment Response to Quetiapine ..........364Caleb Adler

Biological Vulnerability to Indiscriminate/Disinhibited Reactive Attachment Disorder .................................365Stacy S. Drury

A Genome-wide Association Study of Sub-cortical Volumes in Individuals with and without Psychiatric Disorders ..................366Xinmin Liu

Synaptic Strength Regulated by Cytoskeleton Signaling and Risk for Bipolar Disorder: Implications of the Top 500 SNPs from Genome Wide Association Studies . 367Jing Du

BREAKFriday, May 21

2:30 PM – 3:00 PMGrand Ballroom Foyer – 5th Floor

Symposium The Neurobiology of Late- Life Mood Disorders: Biomarkers and AgingFriday, May 213:00 PM – 5:00 PMNottoway - 4th Floor

Chair: Helen LavretskyCo-Chair: Warren D Taylor

3:00 PMThe Brain-Derived Neurotrophic Factor (BDNF) Val66Met Polymorphism in Late-Life Depression: Relationship with Clinical Factors and Biomarkers.............................368Warren D. Taylor

3:30 PMAge-Dependent Alterations of Astrocyte-Associated Intercellular Adhesion Molecule 1 Immunoreactivity in the Orbitofrontal Cortex of Older Subjects with Major Depression.................................................369Jose Javier Miguel-Hidalgo

4:00 PMAmygdala Activation to Emotional Faces in Geriatric Depression..................................370Howard J. Aizenstein

4:30 PMMolecular Imaging in Geriatric Depression....................................................................371Gwenn Smith

Symposium Neurocircuits and Endophenotypes in Obsessive Compulsive DisorderFriday, May 213:00 PM – 5:00 PMBayside A - 4th Floor

Chair: Stephan F Taylor

3:00 PMProbing Frontal Circuitry During Performance Monitoring and Decision-Making in Obsessive-Compulsive Disorder....................................................................372Emily R. Stern

3:30 PM41

Error-Related Brain Activity as an Endophenotype for Obsessive-Compulsive Disorder: Electrocortical Evidence............373Greg Hajcak

4:00 PMIncreased Error-Related Brain Activity and Age at Onset in Pediatric Obsessive-Compulsive Disorder.................................374Gregory L. Hanna

4:30 PMNeural Imaging Markers for Obsessive Compulsive Disorder in Children and Adolescents................................................375Andrew R. Gilbert

Symposium Specificity of Corticolimbic Abnormalities in Adolescents with Major Mood Disorders and Borderline Personality DisorderFriday, May 213:00 PM – 5:00 PMBorgne - 3rd Floor

Chair: Antonia S. NewCo-Chair: Wayne Drevets

3:00 PMThe Structural Development of the Limbic System in Healthy Children and Adolescents................................................376Philip Shaw

3:30 PMStructural Neural Correlates of Depressed Mood in Normal Healthy Children.............377Aaron Boes

4:00 PMAn Altered Developmental Trajectory of Frontotemporal Connectivity in Bipolar Disorder......................................................378Hilary P. Blumberg

4:30 PMAnterior Cingulate Volume Abnormalities in Adolescents with Borderline Personality Disorder - A Potential Biomarker?.............379Marianne Goodman

Symposium

Glucocorticoid Receptor (GR) chaperone-mediated plasticity in health and diseaseFriday, May 213:00 PM – 5:00 PMBayside BC - 4th Floor

Chair: Husseini ManjiCo-Chair: Jing Du

3:00 PMFKBP5 - A Common Candidate Gene for Stress-Related Psychiatric Disorders?.....380Elisabeth B. Binder

3:30 PMBcl-2 Associated Athanogene (BAG-1) Regulates Glucocorticoid Receptor Trafficking to the Mitochondria: Physiology and Pathophysiology.................................381Jing Du

4:00 PMBAG1 and Behavioral Endophenotype Related to Mood Disorder Vulnerability....382Guang Chen

4:30 PMHippocampal Histone Methylation and Stress..........................................................383Richard Hunter

Symposium Glutamatergic System Modulators as Novel Therapeutic Agents for Schizophrenia and Bipolar DisorderFriday, May 213:00 PM – 5:00 PMOak Alley - 4th Floor

Chair: Anantha ShekharCo-Chair: Amit Anand

3:00 PMInteractions of Glutamatergic Amygdalar Afferents with GABA Cells at Key Corticolimbic Loci......................................384Francine Benes

3:30 PMSuppressing Glutamate Release: Preclinical Evidence for Antipsychotic and Antidepressant Effects...............................385Gerard J. Marek

4:00 PM

42

Altered Glutamatetrgic Function in Schizophrenia: New Targets for Drug Development...............................................386Alan Breier

4:30 PMMemantine Augmentation of Lamotrigine Incomplete Response in Bipolar Depression: A Double Blind Placebo Controlled Trial. .387Amit Anand

Symposium Cognitive Neuroscience in the Clinic: Developing Measures of Treatment EffectsFriday, May 213:00 PM – 5:00 PMGrand Ballroom ABC

Chair: Deanna Barch

3:00 PMThe NIMH Perspective on Translational Cognitive Neuroscience.............................388Bruce Cuthbert

3:30 PMTranslational Development of the Relational and Item-Specific Encoding (RISE) Long Term Memory Task.....................................389J. Daniel Ragland

4:00 PMTranslation and Development of a Goal Maintenance Task for Clinical Applications...............................................390Angus MacDonald

4:30 PMTranslational Development and Psychometric Comparison of Two Visual Integration Tasks...........................................................391Steven M. Silverstein

Symposium Molecular, Cellular, and Imaging Studies of Tourette SyndromeFriday, May 213:00 PM – 5:00 PMMaurepas - 3rd Floor

Chair: Bradley S Peterson

3:00 PMFunctional Studies of the Tourette Syndrome-Associated Gene SLITRK1.......392Dorothy E. Grice

3:30 PMDecreased Number of Parvalbumin and Cholinergic Interneurons in the Striatum of Individuals with Tourette Syndrome.........393Flora Vaccarino

4:00 PMAnatomical Disturbances of the Cerebellum in Persons with Tourette Syndrome..........394Russell Tobe

4:30 PM Deficits in Prepulse Inhibition Persist in IndividualsWhose Tourette Syndrome has Remitted ....................................................395James Leckman

Late Breaking Oral SessionBasicFriday, May 213:00 PM – 5:00 PMGrand Couteau – 5th Floor

3:00 PMFunctional Connectomics of the Striatal Medium-Spiny Neuron in Transgenic ChR2 Mice.............................................................396StephenRayport

3:15 PMTransient Neuronal Silencing Reveals Opposing Actions of Indirect and Direct Pathway Neurons ......................................397John F. Neumaier

3:30 PMMitochondrial Somatic Mutations and Haplogroup Susceptibility In Neuropsychiatric Disorders.......................398Marquis P. Vawter

3:45 PMA Novel Deletion in Tropomyosin-related Kinase B (trkb) and the Development of Human Anxiety Disorders..........................399Carl Ernst

4:00 PMHippocampal BDNF Regulates Corticosterone Level and the Behavioral Effects of Chronic Mild Stress ..................400Dekel Taliaz

4:15 PMDepression Increases - and Citalopram Decreases - T-cell HIV Infectivity in Women Ex Vivo .......................................................401Joshua Blume

43

4:30 PMEffect of Childhood Adversity on Neuronal Tryptophan Hydroxylase (TPH2) in Suicide .......................................................402Helene Bach

4:45 PMPsychiatric GWAS Consortium Identifies New Common Gene Variants Conferring Risk of Bipolar Disorder.........................................403Ole A. Andreassen

WorkshopNIMH FundingFriday, May 213:00 PM – 5:00 PMGrand Couteau – 5th Floor

Chair: Mark Chavez

NIMH Funding: Priorities, Opportunities, and Strategies....................................................404

Poster SessionFriday, May 215:00 PM – 6:30 PMGrand Ballroom DE – 5th Floor

Obsessive-Compulsive Symptoms Dimensions Among Patients with and without Tics................................................405Maria Alice De Mathis

Searching for a Uniform Factor Structure for PTSD Symptoms: A Six Factor Model.......406Elbert Geuze

Heritability of Glucose Metabolism in the Rhesus Monkey Brain During Exposure to Potential Threat..........................................407Steven E. Shelton

Effects of Serotonin Transporter and Tryptophan Hydroxylase-2 Gene Variation on the Response to Cognitive-Behavior Therapy in Individuals with Social Anxiety Disorder......................................................408Tomas Furmark

FKBP5 Polymorphism and Childhood Trauma are Associated with Impaired Fear Inhibition....................................................409Tanja Jovanovic

MAO-A and COMT Polymorphisms and OCD: A Brazilian Family-Based Association Study...........................................................410Aline S. Sampaio

SLC6A4 Polymorphism is Associated withTtreatment Response in Obsessive Compulsive Disorder.................................411Roseli G. Shavitt

Genotype-Controlled Analysis of Plasma Dopamine β-Hydroxylase Activity in Civilian Post-Traumatic Stress Disorder................412Yilang Tang

Interaction between Fkbp5 Genotype and Stressful Life Events Predicts Threat-Related Amygdala Reactivity in a Community Sample........................................................413Michael G. White

Cortico-Striatal Substance P Release Correlates with Phobia Related Trait Anxiety........................................................414Fredrik Ahs

Differences in Fear Circuit Connectivity between Responders and Non-Responders to SSRI Treatment of Social Anxiety Disorder - A Bayesian Approach..............................415Thomas Ågren

Neural Effects of Pregabalin in Healthy Controls during Anticipation.....................416Robin L. Aupperle

Impact of Cerebellar Volume in PTSD.......417Leonardo Baldaçara

Parsing the Effect of Anxiety Domains on Limbic Responses to Face Processing.....418Tali M. Ball

Amygdala Response to Familiar, Not Novel, Faces Characterizes Inhibited Temperament..............................................419Jennifer Urbano Blackford

Expectancy and Surprise Influence Attention to Emotional Information...........................420Michael Browning

Cortical Thickness Analysis of Individuals Exposed to Trauma....................................421Vincent Corbo

DTI Studies of Pediatric Maltreatment Related PTSD...........................................................422Michael D. De Bellis

44

Regional Cortical Thickness and Gray Matter Volume as Predictors of Recovery from Post-Traumatic Stress Disorder.........................423Erin W. Dickie

Neuoroticism Modulates the Impact of Anticipatory Anxiety on Experiential, Autonomic, and Neural Responses...........424Emily M. Drabant

Alexithymia and Early Emotional Neglect: The Creation of Alexithymia Subtypes......425Sabine M. Aust

Heightened Amygdala and Hippocampal Responsivity to Emotional Faces in Youth with Posttraumatic Stress Disorder Symptoms: An fMRI Study.........................426Victor G. Carrion

fMRI of Maternal Attachment and the Contribution of Preoccupied Attachment Style to Neuronal Activation......................427Curren Katz

CANDIShare and the Internet Brain Volume Database: Resources for Pediatric Neuroimaging Data....................................428David N. Kennedy

A Multi-Voxel in Vivo 31 P Spectroscopy Study at 4 Tesla in Healthy Children and Adolescents................................................429Brian Martis

Increased Cerebral Blood Flow in White Matter of Females with Familial History of Depression.................................................430Amy E. Ramage

Atlas-Based Analysis and Visualization of Diffusion Properties in Group Studies with Linear Regression Model Over Time.........431Sarah J. Short

Emotion Circuits in the Parental Brain Vary with Gender, Correlate with Mood, and Predict Behavior.........................................432James E. Swain

Social Subordination Stress and Serotonin Transporter Genotype Influence Emotional and Physical Development in Juvenile Female Monkeys.....................................................433Vasiliki Michopoulos

Gender Differences in Autonomic Arousal in Adolescence...............................................434Comfort Elumogo

Gender Differences in Healthy Controls in the Default Mode Network................................435Adrienne Gill

Interferon-Alpha Treatment In Rhesus Macque; The Behavioral, Biochemical and Hematological Effects of Four Weeks of Daily Treatments..................................................436Alex C. Cummins

CRP and Depression: A Test of Alternative Hypotheses.................................................437William Copeland

Reduced Fertility and Fecundity among Patients with Bipolar I Disorder and Schizophrenia in Egypt..............................438Hader Mansour

Serum Levels of Brain-Derived Neurotrophic Factor in Major Depressive Disorder: State and Trait Issues, Clinical Features, and Pharmacological Treatment.......................439Marc L. Molendijk

Allergen-Specific IgE and Allergy Symptoms are Associated with Depression Scores in Patients with Mood Disorders Exposed to Seasonal Pollen-Peaks..............................440Teodor T. Postolache

Mood Disorder Susceptibility Gene CACNA1C Modifies Mood-Related Behaviors in Mice and Interacts with Sex to Influence Behavior in Mice and Diagnosis in Humans....................................................................441David T. Dao

Mice Lacking the Oligodendrocyte-Specific Gene Cnp1 Display a Low Emotionality Phenotype in Two Models of Depression. 442Nicole Edgar

Sodium Pump Alpha2 Isoform Hemideficient Mouse as an Animal Model for Mania.......443Rif S. El-Mallakh

Intermediate Phenotypes for Bipolarity Identified in a Genetically Isolated Population..................................................444Carrie E. Bearden

Genome-Wide Association Analysis Implicates a Chromosome 13 QTL, Near the SLITRK Gene Cluster, in Human Cortical Thickness...................................................445Melanie A. Carless

45

Gene Environment Interactions on Cognitive Reactivity....................................................446Hilal Cerit

Dysfunction of an Astrocyte Gene Network in Suicide........................................................447Carl Ernst

A Meta-Analysis of Association of the Serotonin Transporter Gene (5HTTLPR) with Antidepressant Induced Mania..................448Mark A. Frye

Genome-Wide Combined Linkage/Association Scan Localizes Two QTLs Influencing Human Caudate Volume....................................................................449David C. Glahn

Polymorphisms in the BDNF Gene are Associated with Antidepressant Treatment Response....................................................450Johannes M. Hennings

Fine-Mapping of Genetic Loci Linked to REM-Density in the Munich Vulnerability Study...........................................................451Sonja Horstmann

Comparison of Pharmacogenomic Associations with Clinical Change in Olanzapine/Fluoxetine Combination Treatment of Patients with Treatment Resistant Depression vs. Bipolar I Depression.................................................452John P. Houston

Genome-Wide Association Study of Body Weight in Patients with Major Depression.................................................453Stefan Kloiber

Genome-Wide Gene-Expression Profiles Following Glucocorticoid Stimulation Associated with Major Depression............454Andreas Menke

Depressive Response to Tryptophan Depletion: Lack of Genetic Association with Serotonin Related Candidate Genes.........455Francisco A. Moreno

The Effect of Life Stress on Reward-Related Brain Function is Moderated by 5-HTTLPR Genotype....................................................456Yuliya S. Nikolova

Association between DNA Methylation and Maternal Assessment of Early Childhood Behavior in High-Risk Infants....................457James Schroeder

Relationship Between FKBP5 Polymorphisms and Depression Symptoms Among Kidney Transplant Recipients......458Gen Shinozaki

Elevated Anterior Cingulate Glutamate Associated with SLC1A2 Polymorphisms in Patients with Depression...........................459Marin Veldic

Childhood Abuse and Increased Risk for Anger in Depression during Adulthood: The Moderating Role of MAOA Genotype and Gender........................................................460F. E. Verhoeven

Dopamine Receptor D2 (DRD2) Polymorphism and Psychological Resilience in a Highly Traumatized Urban Population461Aliza P. Wingo

Cholesterol and CSF 5-HIAA in Attempted Suicide........................................................462Peter Asellus

Serotonin Transporter (SERT) Polymorphisms and Corticotropin-Releasing Factor (CRF) Levels in Alcoholism and Suicide........................................................463Carmina G. Bernardo

Serotonin Receptor Levels and Mood States in Alcoholism and Suicide.........................464Carmina G. Bernardo

Serum Levels of Il6, Il10 and Tnf-Alpha in Patients with Bipolar Disorder in Euthymia and with Schizophrenia: Differences in Pro and Anti-Inflammatory Balance.................465Maurício Kunz

MR-Spectroscopy of the Dorsolateral Prefrontal Cortex and Anterior Cingulum of Patients with Major Depression: Comparism with Healthy Controls and Follow-Up after a 4-Week Naturalistic Treatment Period.......466Alexander Luborzewski

Increased Uric Acid Levels in Drug-Naive Subjects with Bipolar Disorder during First Manic Episode............................................467Rodrigo Machado-Vieira

46

CSF 5-HIAA, Childhood Trauma and Violent Behaviour in Suicide Attempters...............468Tomas Moberg

Antidepressant Use in Hypertensive Patients: A Primary Care Study.................................469Suhayl Nasr

The Mao A Transcriptional Repressor, R1, is Decreased in Human Major Depressive Disorder (MDD) and in Chronic Social Stress in Rodents..................................................470Xiao-Ming Ou

Metallothionein Gene Expression and Genetic Variants: Implications for Mood Disorders and Suicide................................471P. Adolfo Sequeira

Lack of Effect of Ketamine on Cortical Glutamate and Glutamine in Healthy Volunteers: A Proton Magnetic Resonance Spectroscopy Study...................................472Matthew J. Taylor

Gender-Specific Gene Expression of a Novel Zinc Finger Transcription Factor, Klf7, in the Prefrontal Cortex of Subjects with Major Depression.................................................473Zhe Wang

Magnetic Resonance Spectroscopy Imaging of Differences Between Unmedicated Bipolar and Unipolar Depression...........................474Amit Anand

Dysregulated Activation of Prefrontal and Limbic Regions in Emotional Processing in Bipolar Disorder: A Meta-Analysis............475John O. Brooks

Mood State Cannot be Ignored in Morphometric Studies of Bipolar Disorder: A Longitudinal Within-Subjects Study of Brain Structure.....................................................476John O. Brooks

Positron Emission Tomography and Functional MRI to Assess Mechanism of Action of Aripiprazole as an Antidepressant Augmentation Agent..................................477Charles R. Conway

Increased Treatment Resistance is Associated with Greater Left Prefrontal Cortex Activation during a Verbal Working Memory Task..............................................478James B. Fox

Neuronal Correlates of Regulation of Emotional Conflict in Women During Menopausal Transition..............................479Benicio N. Frey

T2 Relaxometry in Pediatric Bipolar Disorder......................................................480Atilla Gönenç

Abnormal Reward Prediction Error Signals in Depression and Schizophrenia.................481Victoria Gradin

Urinary Oxytocin is Related to Mother’ EPDS Scores, Neural Response to Infant Images and Feeding Method..................................482Karen M. Grewen

The Modulation of Fear and Empathy Processing by Oxytocin- A Fmri Study in Healthy and Depressed Subjects..............483Simone Grimm

Lithium Shows Large Positive Effect on Dorsolateral Prefrontal Cortex N-acetyl Aspartate in Bipolar Patients.....................484Tomas Hajek

The Long-Term Neuroanatomical Impact of Childhood Emotional Maltreatment...........485Anne-Laura V. Harmelen

Pre-Operative Resting State Functional Connectivity is Associated with Intraoperative Response to Subcallosal Cingulate Deep Brain Stimulation for Treatment-Resistant Depression.................................................486Paul E. Holtzheimer

Atlas-Based Segmentation of White Matter in Major Depressive Disorder Using DTI Collected as Part of Routine Clinical Treatment....................................................487Wouter S. Hoogenboom

Acute Tryptophan Depletion Increases Cingulate Cortex Reactivity in Recovered Depressed Patients - An fMRI Investigation...............................................488Jamie Horder

Neurobiological Markers of Bipolar Disorder: Evidence from Two Neuroimaging Meta-Analyses............................................489Josselin Houenou

47

Effective Connectivity within the Network of Fearful Facial Affect Recognition in Patients with Bipolar Disorder Compared to Healthy Controls......................................................490Matthew Kempton

Persisting Abnormal Lateral PFC Activation in Remitted Depressed Patients During the Performance of an Emotional Working Memory Paradigm......................................491Rebecca V. Kerestes

Prefrontal Subregional Hemodynamic Response and the Correlation with Symptoms and Functioning in Major Depression: A Multi-Channel NIRS Study...........................................................492Masaru Kinou

Underactivation of Cortical-Striatal-Thalamic Circuits in Euthymic Bipolar Patients during Choices to Immediate Monetary Rewards......................................................493Martine Lamy

Abnormal Hippocampal Theta Activity During Spatial Navigation in Bipolar Depression: A Magnetoencephalography Study..............494David R. Latov

Enhanced Neural Responses to Interpersonal Feedback in Patients with Major Depression.................................................495Kyoung-Uk Lee

A Magnetic Resonance Imaging Study of the Effects of Antidepressant Treatment on Brain Structure in Major Depressive Disorder....496Nikolai V. Malykhin

Reduced Neural Response to Reward following 7 Day Treatment with the Cannabinoid CB1 Antagonist Rimonabant in Healthy Volunteers.....................................497Ciara McCabe

Imaging the Mechanisms Underlying Vulnerability to Bipolar Disorder...............498Andrew M. McIntosh

D2/D3 Receptor Polymorphisms Predict Amygdala and Subgenual Cingulate Reactivity to Positive and Negative Emotional Stimuli.......................................499Brian Mickey

Neural Responses to Affective Stimuli are Modulated by NPY Genotype.....................500Brian J. Mickey

Investigation of High Energy Metabolism in Lithium Treated Children with Bipolar Disorder: A 31P MRS Study.......................501Constance M. Moore

Altered Reward Anticipation in Youth At-Risk for Depression Following Winning, Losing, and Neutral Outcomes...............................502Thomas M. Olino

A Voxel Based Morphometry (VBM) Study of Adolescent Offspring with High Family Loading for Major Depressive Disorder....503Rene L. Olvera

Neural Predictors of Depressive Relapse Following Cognitive Therapy....................504Ben Paul

Neural Markers of Early Treatment Response During Antidepressant Treatment in Major Depressive Disorder...................................505Rajamannar Ramasubbu

Mirtazapine Reduces Neural Responses to Fearful Faces in Healthy Volunteers.........506Nancy B. Rawlings

Regional Brain Gray Matter Volume Differences in Patients with Major Depressive Disorder and Patients with Bipolar Disorder Compared to Healthy Controls as Assessed by Voxel-Based Morphometry...................507Francesca Regen

Hypomanic Experience is Associated with Increased dlPFC and ACC Activity to Socially-Threatening Words......................508Philippa L. Rock

Monoamine Oxidase A Inhibitor Occupancy During Treatment of Major Depressive Episodes with Moclobemide and St. John’s Wort: A [11C] Harmine PET Study.............509Julia Sacher

Wisconsin Card Sorting Test, TEMPS-A Inventory and Polymorphisms of 5HTT, BDNF and DAT1 Genes in Patients with Obesity........................................................510Alina Borkowska

48

Psychotropic Medication Use and Hyponatremia in an Inpatient Population. 511Shogyoku Bun

Association between DNA Methylation Patterns and Total Life Stress in Inner City Primary Care Patients................................512Alicia K. Smith

The Effect of Dopamine on Working Memory: Impact of Load, Dose and Genotype.........513Beth M. Anderson

Fronto-Limbic Abnormalities in Adults with Attention-Deficit/Hyperactivity Disorder Comorbid with Bipolar Disorder using a Cortical Thickness MRI Analysis...............514Nikos Makris

Methylphenidate- Mediated Reduction in Prefrontal Hemodynamic Responses to Working Memory Tasks: A Functional Near-Infrared Spectroscopy Study.....................515Rajamannar Ramasubbu

Indices of the Metabolic Syndrome in Healthy Adults: Associations with Hypothalamic-Pituitary-Adrenal Axis Function................516Audrey R. Tyrka

Stress is Visible; Objective Assessment of Stress Based on Multiple Cytokines.........517Atsuo Sekiyama

Dopamine Modulates the Default Mode Network in Parkinson’s Disease................518Philippe Fossati

Reliability of Performance and Fmri Bold Signal in the Cognitive Control Network during the Stroop Task..............................519Tetsuya Takahashi

International Consensus Diagnostic Criteria for Neuroleptic Malignant Syndrome Using the Delphi Technique.................................520Ronald J. Gurrera

FDG-PET Regional Glucose Abnormalities in White Matter in Civilian Impact and Military Blast-Related Mild Traumatic Brain Injury 521Effie M. Mitsis

Subthalamic Nucleus Stimulation in Parkinson’s Disease Induces Apathy: A PET Study...........................................................522Bruno Millet

Transcranial Magnetic Stimulation for Fibromyalgia...............................................523

E. Baron Short

Sensitivity of a Low-Cost Balance Platform for the Assessment of Postural Instability....................................................524Brent Nelson

Phenomenology of Self in Delusions of Reference in Beginning Schizophrenia.....525Aaron Leonard Mishara

Behavioral & fMRI Studies of Prefrontal Cortex in Clinical-High-Risk Early Psychosis...................................................526Tara A. Niendam

Abnormal Face Processing in Schizotypal Personality Disorder..................................527Margaret A. Niznikiewicz

Clinical and Neurocognitive Similarities between the Bipolar and Schizophrenia Prodrome....................................................528Doreen M. Olvet

Baseline Cognitive Performance in Psychiatric Patients and Healthy Volunteers Using a Computerized Neurocognitive Battery........................................................529Gahan Pandina

Recognition of a Facial Affect in a Situation Where Various Emotions Interact with Each Other in Patients with Schizophrenia........530Sung-Hyouk Park

ERN Across the Illness Course of Schizophrenia............................................531Veronica B. Perez

Brain Activation Patterns during Episodic Memory Processing among First Degree Relatives of Schizophrenia Subjects.........532Konasale M. Prasad

Adolescent Offspring of Schizophrenia Patients Show Reduced Amygdala-Related Modulation of Memory Systems During Affective Memory Task...............................533Patrick J. Pruitt

Effect of Rule Maintenance on Episodic Memory in Schizophrenia..........................534J. Daniel Ragland

The Deluded Brain.....................................535Susan RossellA D-Amino Acid Oxidase Diplotype is Associated with Deficient PPI and Attenuated Anxiety in Healthy Males............................536

49

Panos Roussos

Adolescent Schizophrenia Offspring with Prodromal Symptoms Show Hypoactivation in Fronto-Striatal Regions During Sustained Attention Task............................................537Jamie M. Segel

Dissociating Inhibitory Control Deficits in Schizophrenia............................................538Edward E. Smith

Auditory Stream Segregation in Schizophrenia............................................539Joel S. Snyder

Neuroplasticity-Based Cognitive Training Improves Reality Monitoring in Schizophrenia Patients: Behavioral and fMRIAssessments..............................................540Karuna Subramaniam

Sensitization, Epileptic-Like Symptoms and Local Synchronization in Patients with Paranoid Schizophrenia.............................541Marek Susta

Theta Synchronization Abnormalities in Schizophrenia on a Lexical Decision Task............................................................542Grantley Taylor

Factor Analysis of Automatic White Matter Clustering and Neuropsychology Measures in Patients with Schizophrenia..................543Douglas P. Terry

Parametric Variation in Working Memory Demand in Patients With Schizophrenia: A Behavioral and Neuroimaging Pilot Study...........................................................544Jared X. Van Snellenberg

Investigation of Endophenotype Candidates for Schizophrenia: A Study of Magnocellular Pathway in Refractory Patients and their Relatives.....................................................545Fabiana B. Vaz de Lima

Thalamic Volume Predicts Relational Memory Performance ..............................................546Lisa Williams

Task-Positive and Task-Negative Neural Networks Involved in Working Memory Show Decreased Neural Efficiency at a

High Working Memory Loads in Schizophrenia............................................547Todd S. Woodward

Intact Associative Learning in Schizophrenia: Evidence from a Go/NoGo Paradigm....................................................548Austin Woolard

γ−Aminobutyric Acid Concentration is Reduced in Visual Cortex in Schizophrenia and Correlates with Orientation-Specific Surround Suppression..............................549Jong H. Yoon

Prolactin, Smoking Status and Cardiovascular Risk in Community Psychiatric Patients...................................550Paul Mackin

Prenatal Exposure to Herpesviruses and Neuropsychological Outcomes on Schizophrenia............................................551Alan S. Brown

Fetal Exposure to Maternal Stress Hormones and Risk for Schizophrenia: Preliminary Evidence of a Racial Disparity...................552Lauren M. Ellman

First Episode Schizophrenia and Bipolar Disorder Associated with Distinct Personality Trait Profiles...............................................553Ronald J. Gurrera

Behavioral Characterization of Mice in Which Bdnf Promoter-IV Driven Transcription is Impaired......................................................554Keri Martinowich

Copy Number Variation (CNV) of Selenium-Binding Protein (SELENBP)1 in Schizophrenia............................................555Galila Agam

Age at Onset of Schizophrenia and Volume Reduction in Orbitofrontal Gyrus are Associated with UFD1L Polymorphism. . . .556Ary G. Araripe Neto

Neurodevelopment in Adolescence and Young Adulthood (NAYA): Relationship Between Prodromal Symptoms and Self-Reported Schizotypal Symptoms in Youths At-Risk for Psychosis................................557Monica E. Calkins

50

Lithium Modulation of Gene Expression in Bipolar Disorder.........................................558Cristiana Cruceanu

Association of Plasma Dopamine β-Hydroxylase and Variants at the DBH Gene with Differences in Factor Scores Representing Clinical Features of Schizophrenia............................................559Joseph F. Cubells

Cross-Phenotype Analysis of 380 Candidate Gene Markers in Schizophrenia: Evidence of Genetic Effect on the Age at Onset...........560Vincenzo De Luca

Tag-SNP Based Study of 109 Candidate Genes for Schizophrenia Selected Using an Evidence-Based Prioritization Algorithm. .561Ayman Fanous

Association of DISC1 Genetic Variation with Intermediate Phenotypes in Neuroimaging: Replication and Further Extension............562Oliver Gruber

A Multimodal Assessment of the Genetic Control over Working Memory..................563Katherine H. Karlsgodt

The Replication of Egr3 as a Potential Susceptibility Gene for Schizophrenia in Korean Patients with Schizophrenia.........564Yong Sik Kim

A Schizophrenia Risk Gene, ZNF804A, Influences Neuroanatomy and Neurocognition..........................................565Todd Lencz

Impact of PLA2 Gene Polymorphisms on Onset of Schizophrenia and Illness Severity.......................................................566Sergej Nadalin

Allelic Variations in ANK3 and CACNA1C Impact on Spatial Working Memory, Startle Reactivity and Personality Traits in Healthy Males...........................................................567Panos Roussos

Myelin Associated Glycoprotein Gene Influences White Matter Phenotypes in Schizophrenia............................................568Aristotle Voineskos

Association Analysis of Polymorphisms on Nogo-66 Receptor (RTN4R) Gene with Schizophrenia in the Korean Population. .569Sung-il Woo

Association Analysis of Polymorphisms on Proline Dehydrogenase (PRODH) Gene with Schizophrenia in the Korean Population. .570Sung-il Woo

GABA System Genes in Tardive Dyskinesia..................................................571Clement C. Zai

Sex-Sepcific Association of ZNF804A with Schizophrenia............................................572Fengyu Zhang

Meta-Analysis Provides Support for a Relationship between Genetic Variation in DTNBP1 and General Cognitive Ability.....573Jianping Zhang

Biomarkers of Oxidative Stress in Chronic Stabilized Patients with Schizophrenia and Euthymic Patients with Bipolar Disorder. .574Keila M. Ceresér

Biomarkers of Oxidative Stress in Early and Late Stages of Schizophrenia....................575Clarissa S. Gama

The Effects of Sleep Restriction on Daytime Performance: A Double-Blind Comparison of Eplivanserin, Placebo, or Temazepam......576Michael J. Peterson

Ambulatory Polysomnography to Investigate Obstructive Sleep Apneoa (OSA) in Secondary Care Community Service Patients.......................................................577Paul Mackin

Screening for Obstructive Sleep Apnea in Psychiatric Outpatients.............................578Suhayl Nasr

Caffeine Reduces Behavioral Risk-Taking During Sleep Deprivation...........................579William D. Killgore

From Orexin Cells and Sleep Circuits to Clinical Therapy for Insomnia...................580Christopher J. WinrowThe Impact of Body Dysmorphic Disorder Comorbidity in Patients with Obsessive-Compulsive Disorder.................................581Roseli G. Shavitt

51

Childhood Family Function Predicts Dopamine Response to d-Amphetamine Challenge: A PET [11C] Raclopride Study..582Kevin F. Casey

Orbitofrontal Volume, Decision-Making, and Cannabis Abuse in Adolescence...............583John C. Churchwell

Response Inhibition in Healthy Individuals with a Family History of Alcoholism.........584Elise E. DeVito

An Interaction between Response to Reward in the Ventral Stratum and a Prodynorphin VNTR Polymporphism Predict Alcohol Consumption..............................................585Adam Gorka

A Proton Magnetic Resonance Spectroscopy Investigation of Substance Induced Psychosis...................................................586Bonnie Lichlyter

Lower Perfusion Detected with Arterial Spin Labeling in Young Abstinent Stimulant Abusers......................................................587Kelvin O. Lim

Association Between 5HT1B Receptors and Cocaine Dependence in Human Subjects......................................................588David Matuskey

Amygdalar Volume Correlates with Depression in Marijuana Users..................589Erin McGlade

Abnormal Error Processing in Current and Former Cocaine Users: An fMRI Based Study...........................................................590Shashwath A. Meda

Altered Glutamate/Gaba Relationship in the Cingulate of Marijuana Users....................591Andrew P. Prescot

MDMA (Ecstasy) use is Associated with Increased Signal Intensity in Anterior Cingulate Gyrus during Flanker Task Performance: An fMRI Study.....................592Erin E. Toaz

Combining a fMRI-Based Reward Processing Task and C11-Raclopride PET to Identify the Role of Ventral Striatal Dopaminergic Mechanisms in Reward Processing - Preliminary Data.........................................593Michael J. Travis

Deficits in Perception and Motor Production of Facial Affect in Schizotypal Personality Disorder......................................................594Chandlee C. Dickey

Sub-Diagnostic Psychiatric Comorbidity Vs. Psychiatric Diagnoses in Alcoholism.......595George Fein

Neuropsychology of the Schizo-Obsessive Subtype of Schizophrenia: New Findings.596Naomi A. Fineberg

Imaging and Cognitive Tasks in Clinical Interventions for Female-Specific Mood Disorders....................................................597Benicio N. Frey

Arginine Vasopressin Influences on the Recognition of Social Words.....................598Adam J. Guastella

Heart Rate Variability in Depression: Effects of Escitalopram..........................................599Angelos Halaris

Carbon Dioxide Induced Panic in Schizophrenia with Auditory Hallucinations............................................600Jeffrey P. Kahn

Neural Predictors of Treatment Response in Major Depression using fMRI....................601Paul Keedwell

A Role for Oxytocin in the Acute and Long-Term Social Effects of Recreational Drugs..........................................................602Iain S. McGregor

Age-Dependent Alterations of Astrocyte-Associated Intercellular Adhesion Molecule 1 Immunoreactivity in the Orbitofrontal Cortex of Older Subjects with Major Depression.................................................603Jose Javier Miguel-Hidalgo

Affective-Neurophilosophical Foundations of Depression and Cross-Species Emotional Endophenotypes........................................604Georg Northoff

Aripiprazole Treatment of Co-Occurring Social Anxiety in Schizophrenia................605Stefano Pallanti

Comorbid Panic Attacks and Schizophrenia: Implications for Symptoms and Cognition606Erica Rapp

52

Animal Models to Investigate Biomarkers of Antidepressant Treatment Response........607Etienne Sibille

Late Breaking PostersImagingFriday, May 215:00 PM – 6:30 PMGrand Ballroom DE – 5th Floor

At the time of publication, these abstracts were not available to include in the program book. Please see the On-Line Program Planner at www.sobp.org to view the abstract.

Differential Timing in Medial Prefrontal Cortex and Fusiform Gyrus Activation in Schizophrenia Offspring ...........................608Darren L. Croo

Impaired Prefrontal Activation and Frontolimbic Connectivity in Young.........609Zola N. Mannie

High Resolution MEG Source Imaging Analysis for Auditory Processing Abnormalities in Schizophrenia................610Michael A. Hunter

Effects of HPA-Axis Reactivity on Reward Processing in Girls at Low and High Risk for Depression ................................................611

Per2 Genotype and Circadian-Related Neural Response to Reward in Adolescents........612Erika E. Forbes

Genetic Modulation of Brain Response to Working Memory Task in Healthy Individuals .................................................613Wissam El-Hage

Relationship between Suicidality and Impulsivity in Bipolar I Disorder: a Diffusion Tensor Imaging Study ...............................614Philip R. Szeszko

Power Spectrum Scale Invariance Identifies Prefrontal Dysregulation in Paranoid Schizophrenia ...........................................615Anca R. Radulescu

Evidence of Dopamine Dysregulation in PTSD: The First In Vivo Dopamine Transporter Study using SPECT with [99mTc]TRODAT-1 .......................................616Marcelo Q. Hoexter

Proton Magnetic Resonance Spectroscopy to Evaluate the Neuroprotective Potential of AL-108 in DLPFC in Schizophrenia ................617L. Fredrik Jarskog

Reduced Gray Matter Volume In s’ Allele Carriers Of The 5-httlpr Triallelic Polymorphism: A Large (n = 113) 3t Vbm Study ..........................................................618Beata R. Godlewska

Brain Activity during Deception in Psychopathy: Lying about Oneself and One’s Crimes ........................................................619Andrea L. Glenn

Regional Hippocampal Dysfunction in Schizophrenia and Mouse Models of Disease: Evidence from In Vivo Human Functional MRI, Mouse Functional MRI, and Extracellular Glutamate Monitoring..........620Scott A. Schobel

Imaging the Aha! Moment: A Novel fMRI Task Measuring Reasoning and Problem Solving .......................................................621David R. Goldsmith

Coil placement to target the Dorsolateral Prefrontal Cortex in rTMS: an improvement of the reference technique ........................622Vincent MEILLE

Diffusion Tensor Imaging and Tractography in Adolescent-Onset Borderline Personality Disorder .....................................................623Marianne Goodman

Diffusion Tensor Imaging in OIF/OEF Combat Veterans With Blast-related Mild Traumatic Brain Injury With And Without PTSD........624Effie M. Mitsis

Commonalties and Differences of Two Psychotic Phenotypes Using Connectivity fMRI ............................................................625Jack R. Foucher

Brain Activity During Theory of Mind and Moral Judgment Tasks in Individuals with Schizophrenia, their Nonpsychotic Siblings, and Healthy Controls.................................626Salvador M. Guinjoan

Impaired facial discrimination in Major Depressive Disorder and the effects of Acute

53

Antidepressant Administration in Healthy Subjects .....................................................627Poornima Kumar

Proton Magnetic Resonance Spectroscopy (1h-mrs) Assessment of the Neurochemical Profile in Rat Brain after Traumatic Brain Injury (TBI) .................................................628Katrina Fenton

Is Decline in Neurocognitive Functioning More Likely To Be An Endophenotype Than Serum BDNF Levels in Bipolar Disorder?.629Aysegul Ozerdem

Error-Related ERPs Track Evaluation of Non-Reward and Punishment in Schizophrenia............................................630Philip B. WardSex differences in Dopamine D2 Receptor Occupancy in the Amygdala using PET and [18F]fallypride.............................................631Patrizia Riccardi

BDNF Serum Concentrations do not Correlate with Brain Volume Changes or Disease Severity in Neurodegenerative Disease ......................................................632Eric V. Strobl

Welcome ReceptionFriday, May 216:45 PM – 8:15 PMArmstrong Ballroom – 8th Floor

Welcome reception for all registered attendees and paid guests. Appetizers and cocktails will be provided. Please join us for this reception to mingle and relax with your friends and colleagues before going out to enjoy your dining and entertainment options in New Orleans.

54

Saturday, May 22

Continental BreakfastSaturday, May 227:00 AM – 8:00 AMGrand Ballroom Foyer – 5th Floor

RegistrationSaturday, May 227:00 AM – 5:00 PMGrand Ballroom Foyer – 5th Floor

Speaker-Ready RoomSaturday, May 227:30 AM – 5:00 PMEdgewood AB – 4th Floor

Plenary Session – SchizophreniaSaturday, May 228:00 AM – 10:15 AMGrand Ballroom ABC – 5th Floor

Chair: Stephan Heckers, MD

8:00 AMAssembly of GABAergic Inhibitory Circuits in Neocortex and Implications in Neurodevelopmental Disorders.................633Z. Josh Huang, PhDCold Spring Harbor Laboratory

8:45 AMThe Hippocampal Circuit in Schizophrenia and Beyond................................................634Scott A. Small, MDColumbia University

9:30 AMAllosteric Modulators of GPCRS as a Novel Approach to Treatment of Schizophrenia............................................635P. Jeffrey Conn, PhDVanderbilt University

BreakSaturday, May 2210:15 AM -10:45 AMGrand Ballroom Foyer – 5th Floor

Presidential LectureSaturday, May 22

10:45 AM - 11:45Grand Ballroom ABC – 5th Floor

Chair: Stephan Heckers, MD

Can we Understand the Epidemiology of Schizophrenia in Terms of the Pathophysiology of Striatal Dopamine? . .636Robin Murray, FRCPsych, DScInstitute of Psychiatry

Lunch/NetworkingSaturday, May 2211:45 AM – 12:30 PMGrand Ballroom Foyer – 5th Floor

Box lunches will be available for all registered attendees.

Symposium Implicit Emotion Regulation: Basic Mechanisms and Clinical RelevanceSaturday, May 2212:30 PM - 2:30 PMBayside A - 4th Floor

Chair: Amit EtkinCo-Chair: Mary Louise Phillips

12:30 PMBidirectional Control of Fear Expression in Prefrontal-Amygdala Circuits....................637Greg J. Quirk

1:00 PMNeural Circuitry for Emotional Conflict Adaptation and its Impairment in Generalized Anxiety and Related Conditions................638Amit Etkin

1:30 PMWhite Matter and Genetic Contributions to Regulation Deficits Affecting Anticipatory Brain Function in Generalized Anxiety Disorder......................................................639Jack B. Nitschke

2:00 PMDissociable Patterns of Abnormal Connectivity in Implicit Emotion Regulation Neural Circuitry in Adult Bipolar and Unipolar Depression and Mood Disorder at Risk Youth..........................................................640Mary Louise Phillips

Symposium 55

From Circuits to Clinical Recovery: Prefrontal-Amygdala Pathways as Targets for Intervention in Anxiety and Mood DisordersSaturday, May 2212:30 PM - 2:30 PMOak Alley - 4th Floor

Chair: K. Luan PhanCo-Chair: Amit Anand

12:30 PMPrefrontal Pathways for Emotions through the Amygdala and Temporal Cortex..........641Helen Barbas

1:00 PMIntegrity of Amygdala-Prefrontal Pathways and Trait Anxiety........................................642Paul Whalen

1:30 PMFrontal-Amygdala Targets for Intervention in Social Anxiety Disorder.............................643K. Luan Phan

2:00 PMEffect of Antidepressants and Mood Stabilizers on Corticoamygdalar Connectivity....................................................................644Amit Anand

Symposium Neurobiological Factors in Antisocial Groups: Recent Research and Clinical ImplicationsSaturday, May 2212:30 PM - 2:30 PMNottoway - 4th Floor

Chair: Birgit Angela Vollm

12:30 PMImaging Fronto-Limbic Structure, Function and Serotonin in Antisocial Personality Disorder......................................................645J. F. William Deakin

1:00 PMNeuroimaging Investigations of Children Characterized by Antisocial Behaviour and Callous-Unemotional Traits.......................646Stephane A. De Brito

1:30 PMMoral Sentiments, Prosocial and Antisocial Behavior: New Imaging Evidence..............647Jorge Moll

2:00 PM

Impairment in the Functional and Structural Connections between the Amygdala and Orbital Frontal Cortex in Conduct Disordered Youth with Callous and Unemotional Traits...........................................................648James Blair

Symposium Glutamate in OCD: New findingsSaturday, May 2212:30 PM - 2:30 PMMaurepas - 3rd Floor

Chair: Christopher Pittenger

12:30 PMGenetics of OCD: A New Focus on Glutamate...................................................649Gerald Nestadt

1:00 PMNew Insight into the Dynamics of Striatal Glutamate Dysfunction in a Mouse Model of OCD........................................................650Guoping Feng

1:30 PMGlutamate Modulating Agents in Treatment-Refractory Obsessive-Compulsive Disorder......................................................651S. Evelyn Stewart

2:00 PMTargeting Glutamate in OCD Treatment: Studies in Patients and Animal Models. . . .652Christopher Pittenger

Symposium Craving, Compulsion and Consumption: Evolved Neurobiology in Disorders of DesireSaturday, May 2212:30 PM - 2:30 PMGrand Couteau - 5th Floor

Chair: Ronald L CowanCo-Chair: Anna Rose Childress

12:30 PMDesire Disorders: “Dirty Deeds” of a Highly Evolved Brain?...........................................653Joseph Frascella

1:00 PMDrug Addiction and Obesity: Results of Maladaptation to Modern Environment?...654Gene-Jack Wang

1:30 PM

56

Rising Passions: Overlapping Brain Substrates for Drug and Sexual Reward...655Anna Rose Childress

2:00 PMReward Substitution Treatment: Exercise Reduces Cannabis Craving and Cue Activation...................................................656Ronald L. Cowan

Symposium Paradigms Lost: Post-Genomic Longitudinal Studies of Mood DisordersSaturday, May 2212:30 PM - 2:30 PMBorgne - 3rd Floor

Chair: Melvin G. McInnis

12:30 PMAdolescents at Risk for Bipolar Disorder: Experience from the NIMH Bipolar Genetics Initiative......................................................657John Nurnberger

1:00 PMLessons Learned: The Collaborative Study of Depression, 25 Years on............................658William Coryell

1:30 PMSTEP-BD: Lessons Learned, Outcomes and Directions...................................................659Michael J. Ostacher

2:00 PMPrechter Bipolar Respository and Longitudinal Study of Bipolar Disorder....660Melvin McInnis

Symposium Neuroimaging Monoamine Dysregulation: Implications for Symptoms of Mood and AddictionSaturday, May 2212:30 PM - 2:30 PMGrand Chenier - 5th Floor

Chair: Jeffrey MeyerCo-Chair: Eugenii A Rabiner

12:30 PMMonoamine Oxidase a Binding in Major Depressive Disorder and in Cigarette Withdrawal..................................................661Jeffrey Hugh Meyer

1:00 PM

Effect of a Major Depressive Disorder History and of Bupropion Treatment on Smoking-Induced Dopamine Release.......................662Arthur Brody

1:30 PMVentral Striatal Serotonin 1B Receptor Binding in Alcohol Dependence and Major Depressive Disorder...................................663Alexander Neumeister

2:00 PMImaging Monoaminergic Molecular Targets: Target Availability and Functional Information.................................................664Eugenii A. Rabiner

Symposium Clinical Staging and the Need for Holistic Interventions in Emerging Mental DisordersSaturday, May 2212:30 PM - 2:30 PMBayside BC - 4th Floor

Chair: Husseini ManjiCo-Chair: Patrick D McGorry

12:30 PMFrom Prevention to Preemption................665Thomas Insel

1:00 PMClinical Staging and Preventive Interventions in Psychiatry...............................................666Patrick D. McGorry

1:30 PMWhy do Mental Disorders Emerge in Adolescence?.............................................667Matcheri Keshavan

2:00 PMNeuroplasticity-Based Cognitive Training in Early Psychosis..........................................668Sophia Vinogradov

Symposium Hippocampal Dysfunction in PsychosisSaturday, May 2212:30 PM - 2:30 PMGrand Ballroom ABC

Chair: Christine Konradi

12:30 PM

57

Abnormalities in Gaba Neuron Populations in the Hippocampus in Bipolar Disorder: Potential Relationship with Mitochondrial Abnormalities.............................................669Christine Konradi

1:00 PMNew Data to Model the Role of the Hippocampal Formation in Schizophrenia Psychosis...................................................670Carol A. Tamminga

1:30 PMMolecular Mechanisms Underlying CA1 Hypermetabolism in Schizophrenia..........671Scott A. Small

2:00 PMThe Role of Kainate Receptors (KRs) in Regulating the Interplay of Inhibitory and Dysinhibitory Gaba Cells in the Hippocampus of Schizophrenic and Bipolar Subjects......................................................672Francine M. Benes

Oral Session Mood DisordersSaturday, May 2212:30 PM - 2:30 PMSouthdown - 4th Floor

12:30 PMReduced Metabotropic Glutamate Receptor 5 in Major Depression...................................673Gregor Hasler

12:45 PMEffort-Based Decision-Making as a Behavioral Assay of Mesolimbic Dopamine Function and Motivational Deficits in MDD....................................................................674Michael T. Treadway

1:00 PMAltered SST and VGF Gene Expression in Anterior Cingulate Cortex of Post-Mortem Human Subjects with Recurrent Major Depression.................................................675Adam C. Tripp

1:15 PMThe Serotonin Transporter Promoter Variant (5-HTTLPR), Stress, and Depression Meta-Analysis Revisited: Evidence of Genetic Moderation.................................................676Srijan Sen

1:30 PMAssessing Neural Circuit Correlates of Intraoperative Behavioral Response to Deep Brain Stimulation of the Subcallosal Cingulate for Depression...........................677David A. Gutman

1:45 PMThe Galanin Receptor 1 (GalR1) Gene Associates with Tobacco Craving in Smokers Seeking Treatment Cessation Therapy.....678Adriana Lori

2:00 PMNeural Correlates of Habit Learning and Reward Processing in Cocaine Users.......679Gregory Tau

2:15 PMEfficacy of Magnetic Seizure Therapy in Depression.................................................680Sarah Kayser

BreakSaturday, May 222:30 PM – 3:00 PMGrand Ballroom Foyer – 5th Floor

SymposiumDevelopment and Use of Model Based Reward Brain Imaging Studies in Eating DisordersSaturday, May 223:00 PM - 5:00 PMGrand Couteau - 5th Floor

Chair: Guido Klaus FrankCo-Chair: Randall C. O'Reilly

3:00 PMOrbitofrontal-Dopaminergic Interactions and Adaptive Behavior in Rats.........................681Geoffrey Schoenbaum

3:30 PMComputer Models of Reward Expectation and Outcome Processing in the Brain.............682Randall C. O'Reilly

4:00 PMImplementation of Models into the fMRI Environment...............................................683Samuel M. McClure

4:30 PMModel Based fMRI in Anorexia Nervosa....684Guido K.W. Frank

58

Symposium Translating Genomics to Healthcare: The Pharmacogenomics of DepressionSaturday, May 223:00 PM - 5:00 PMBayside BC - 4th Floor

Chair: Julio LicinioCo-Chair: Elisabeth B Binder

3:00 PMSequence Variability in ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1, NTRK2 and BDNF: Novel Variations and Association with Depression and Antidepressant Response....................................................685Julio Licinio

3:30 PMGenetic Studies of Antidepressant Response and Side Effects in the STAR*D Study......686Steven P. Hamilton

4:00 PMModels that Incorporate Genetic and Clinical Variables Improve Prediction of Antidepressant Outcome...........................687Francis J. McMahon

4:30 PMConvergent Evidence for the Genetics of Antidepressant Treatment Response and Side Effect Profiles: Data from the MARS and STAR*D Cohorts.........................................688Elisabeth B. Binder

Symposium Mg2+-Regulation - Interface between Neuroendocrine, Metabolic and Glutamatergic Mechanisms of Major Depression?Saturday, May 223:00 PM - 5:00 PMNottoway - 4th Floor

Chair: Harald MurckCo-Chair: Nicolas Singewald

3:00 PMMagnesium- and Zinc-Deficiency Models for Depression: Involvement of NMDA/NO Pathways....................................................689Nicolas Singewald

3:30 PMMagnesium and Glutamate Interaction in Depression and Antidepressant Therapy. 690Gabriel Nowak

4:00 PMMagnesium and Abnormal Brain Bioenergetics in Major Depression...........691Perry F. Renshaw

4:30 PMAldosterone in Relation to Mood Disorders....................................................692Daniela Jezova

Symposium New Directions in Suicide NeurobiologySaturday, May 223:00 PM - 5:00 PMBorgne - 3rd Floor

Chair: Yogesh DwivediCo-Chair: Ghanshyam N. Pandey

3:00 PMEffects of Suicide and Childhood Adversity on Adult Neurogenesis..............................693Victoria Arango

3:30 PMEpigenetic Mechanisms in Suicide: A Genome-Wide Study..................................694Gustavo Turecki

4:00 PMCorticotropin Releasing Factor and Glucocorticoid Receptors in the Postmortem Brain of Teenage Suicide Victims.............695Ghanshyam N. Pandey

4:30 PMRole of Extracellular Signal-Regulated Kinase (ERK) Signaling in Suicide Pathogenesis..............................................696Yogesh Dwivedi

Symposium Discovering Imaging Endophenotypes for Affective DisordersSaturday, May 223:00 PM - 5:00 PMOak Alley - 4th Floor

Chair: Gregor HaslerCo-Chair: Helen S. Mayberg

3:00 PMCortical-Subcortical Connetivity and Genetic Risk for Bipolar Disorder...........................697Andreas Meyer-Lindenberg

59

3:30 PMMood Reactivity in Major Depression: A Psychopathological Endophenotype?......698Helen S. Mayberg

4:00 PMReduced Cortical GABA Concentration as Putative Endophenotype in Major Depression.................................................699Gregor Hasler

4:30 PMDefault Network Activity and the Risk of Self-Pathology...................................................700Georg Northoff

Symposium Oxidative-Stress and Inflammation in Schizophrenia: From NMDA and Parvalbumin-Interneurons to Drug TargetsSaturday, May 223:00 PM - 5:00 PMMaurepas - 3rd Floor

Chair: Kim Q. DoCo-Chair: Akira Sawa

3:00 PMActivation of the IL-6/Nox2 Pathway Mediates the Loss of Fast-Spiking Interneurons in Schizophrenia Models...............................701Margarita Behrens

3:30 PMPrenatal Infection Links GABAergic and Glutamatergic Dysfunctions to Cognitive Impairments Relevant to Schizophrenia. . .702Joram Feldon

4:00 PMActivation of Oxidative Stress-Associated Cascades in Cells from Patients with Schizophrenia, being Modified by Schizophrenia Genetic Risk Factors.........703Akira Sawa

4:30 PMRedox Dysregulation and Oxidative Stress Affects Parvalbumin Interneurons and Neural Synchrony: A Reverse Translational Approach towards New Drug Target.........704Kim Q. Do

Symposium Novel Neuroimaging Approaches: Towards Personalized Patient CareSaturday, May 223:00 PM - 5:00 PMBayside A - 4th Floor

Chair: Mary Louise Phillips

3:00 PMUsing in Vivo Tractography to Optimize Subcallosal Cingulate Deep Brain Stimulation for Treatment-Resistant Depression.................................................705Paul E. Holtzheimer

3:30 PMData Mining Resting State Corticolimbic Connectivity to Predict Treatment Response in Unipolar and Bipolar Depression..........706Amit Anand

4:00 PMUsing Pattern Recognition Approaches to Classify Groups of Subjects Based on the Whole Brain fMRI.......................................707Janaina Mourao-Miranda

4:30 PMPrefrontal -Amygdala Connectivity Abnormalities Differentiate Depression in Bipolar Disorder and Major Depressive Disorder......................................................708Jorge Renner Cardoso Almeida

Symposium Amygdala Regulation in the Context of Acute Stress and Pathological StatesSaturday, May 223:00 PM - 5:00 PMGrand Chenier - 5th Floor

Chair: Bernet ElzingaCo-Chair: Paul Whalen

3:00 PMRegulating the Human Amygdala: From Normal to Pathological Responses...........709Paul Whalen

3:30 PMTracking Amygdala Processing when Individuals are Stressed............................710Guillén Fernández

60

4:00 PMAmygdala Regulation During Somatosensory Stimulation: A Possible Link to the Understanding of Self-Injurious Behavior.....................................................711Christian Schmahl

4:30 PMThe Dampening Effect of Acute Dissociation on Amygdala Responsiveness in Traumatized Patients with Borderline Personality Disorder......................................................712Bernet M. Elzinga

Symposium Dopamine Dysfunction in Schizophrenia- From Human Imaging to Animal ModelsSaturday, May 223:00 PM - 5:00 PMGrand Ballroom ABC

Chair: Neil Woodward

3:00 PMThe Dopamine Dysfunction in Schizophrenia: Effects of Antipsychotics and Comorbid Substance Abuse.......................................713Anissa Abi-Dargham

3:30 PMIn Vivo Imaging of Dopaminergic Function and Longitudinal Changes from the Prodrome to Psychosis.............................714Oliver D. Howes

4:00 PMDopaminergic Function and Schizotypal Personality Traits in Healthy Individuals. .715Neil Woodward

4:30 PMNormal and Pathological Transitions in Dopamine System Function Across Adolescence in Rodent Models.................716Holly Moore

Oral SessionAnxiety DisordersMay 22, 20103:00 PM - 5:00 PMSouthdown - 4th Floor

3:00 PMOxytocin Attenuates Amygdala Response to Fear in Social Anxiety Disorder.................717

Izelle Labuschagne3:15 PMIntranasal Oxytocin Improves Specific Recognition of Positive Facial Expressions................................................718Abigail A. Marsh

3:30 PMMilitary Deployment Increases Amygdala Reactivity: A Prospective Functional MRI Study...........................................................719Guido van Wingen

3:45 PMSocial Support Moderates the Link Between Amygdala Reactivity and Trait Anxiety in a Community Sample....................................720Luke W. Hyde

4:00 PMThe Epigenetic Signature of Depression at the Serotonin Transporter is Dependent on Gender........................................................721Robert Philibert

4:15 PMBalance of 5-HT1A and 5-HT2A Predicts Threat-Related Amygdala Reactivity.....................722Patrick M. Fisher

4:45 PMTemporal Discounting of Rewards in Patients with Bipolar Disorder and Schizophrenia. 724Brian F. O'Donnell

Poster SessionSaturday, May 225:00 PM - 6:30 PMGrand Ballroom DE – 5th Floor

Age and Sex Differences in NK1 Receptor Availability Assessed with [11C]GR205171...........................................725Jonas Engman

Limbic/Paralimbic Targets for Breathing Modulation: A Proof of Concept fMRI Study for Panic Disorder......................................726Karleyton C. Evans

Changes in Neural Response to Trauma-Related Reminders in Patients with Posttraumatic Stress Disorder Following Paroxetine Treatment.................................727Negar Fani

61

OEF/OIF Veterans with PTSD Relative to Those without Fail to Mount Activation to Anticipating Temporally Uncertain Emotional Events.........................................................728Taru M. Flagan

Gray Matter Changes in Drug- Drug-Naïve OCD Patients before and after a Randomized Trial with Fluoxetine or Cognitive Behavioral Therapy.......................................................729Marcelo Hoexter

Evidence for Reduced Serotonin Transporter Expression in Posttraumatic Stress Disorder......................................................730Jian Hu

Mindfulness in Combat PTSD: Effect of Mindfulness-Based Therapy in Vietnam Veteran and Neural Correlates of Self-Report Mindfulness" in OEF/OIF Veteran PTSD Patients".....................................................731Rebecca E. Kaufman

Paralimbic Responses to Masked Emotional Faces in PTSD: Disorder and Valence Specificity...................................................732William D. Killgore

Neurocircuitry of Emotional Regulation in OEF/OIF Veterans with PTSD: Effects of Diagnosis and 5-HTTLPR Genotype..........733Anthony P. King

Aversive Stimuli and Functional Networks of Fear Learning in PTSD...............................734Clas Linnman

Functional Abnormalities in the Neural Circuits Underlying Obsessive-Compulsive Disorder......................................................735Rachel Marsh

The Influence of Gonadal Hormones on Conditioned Fear Extinction in Healthy Humans, an fMRI Study.............................736Mohammed R. Milad

Combat Deployment Effects on Threat-Related Amygdala Reactivity.....................737Karen E. Muñoz

Neural Responses to Instructed Fear in PTSD and Resilience............................................738James W. Murrough

Anxiety Sensitivity Correlates with Insular Cortex Volume and Thickness in Specific Animal Phobia............................................739

Isabelle M. Rosso

Altered Connectivity in Resting State Networks in Obsessive-Compulsive Disorder......................................................740Stephan F. Taylor

Glucocorticoid Receptor Binding to Peripheral Blood Mononuclear Cells from Military Personnel before Deployment to Afghanistan Predicts PTSD Symptoms 6 Months after Deployment...........................741Elbert Geuze

Cortisol in Hair: A Retrospective Measure of Cortisol Levels Over Prolonged Periods of Time............................................................742Clemens Kirschbaum

Gamma Ventral Capsulotomy for Obsessive Compulsive-Disorder: Interim Results of a Randomized Controlled Trial.....................743Antonio C. Lopes

Elevated Cortisol Levels after Motor Vehicle Collision Predict Post Traumatic Stress Disorder and Depressive Symptoms at 1 Month..........................................................744Omar Halawa

Attentional Bias to Angry Faces in OEF/OIFF Combat Veterans using Eye-Tracking.......745Tim A. Kimbrell

Gender Differences in the Anxious Response to Predictable and Unpredictable Aversive Events in Children and Adults...................746Anja Schmitz

Acute Hydrocortisone Increases Anxiety but not Fear in Healthy Humans......................747Elizabeth Hirschhorn

Potential Differences in Pharmacogenomic Associations with Improvement in Anxiety During Duloxetine Treatment of Generalized Anxiety Disorder and Major Depressive Disorder......................................................748Roy H. Perlis

The Role of Catechol-O-Methyltransferase (COMT) in Modulating Hippocampal Dopaminergic Metabolism and Behaviour...................................................749Linda M. LaatikainenExamining Generalization of Conditioned Fear Across Generalized Anxiety Disorder, Social Anxiety Disorder, and Panic Disorder......................................................750Elizabeth W. Hirschhorn

62

Effect of Supplementary Motor Area Modulation on Motor Cortex Excitability in Obsessive-Compulsive Disorder: Relations to Clinical Improvement.............................751Antonio Mantovani

Heart Rate and Respiratory Response to Doxapram in Patients with Panic Disorder......................................................752Jose M. Martinez

History of Clinical Anxiety Blunts Blood Pressure Reactivity to Laboratory Mental Stress in Adolescents and Young Adults. 753Susanna L. Quasem

Through the Gates of the Amygdala: A Multi-Node Circuitry Study of Anxiety................754Youngsun T. Cho

mRNA and Protein for GABAAα4, α5, β1 and GABABR1 are Reduced in Brains from Subjects with Autism.................................755Seyyed H. Fatemi

Effects of Guanfacine Extended Release in Children Aged 6 to 12 Years with Oppositional Symptoms and a Diagnosis of Attention-Deficit/Hyperactivity Disorder. . .756Daniel Connor

Effects of the Histamine Inverse Agonist MK-0249 in Adult Attention Deficit Disorder: A Randomized, Controlled, Crossover Study...........................................................757W. Joseph Herring

Twenty-Four-Month Effectiveness of Guanfacine Extended Release in Children and Adolescents Aged 6 to 17 Years with Attention-Deficit/Hyperactivity Disorder. . .758Floyd Sallee

Efficacy, Safety and Tolerability of Paliperidone ER in Adolescent Patients with Schizophrenia............................................759Jaskaran B. Singh

Response to Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD).......760John TurnbowThe Interface of Emotion and Self-Image: Visual Self-Recognition Across Development in Child and Adolescent Bipolar Disorder 761Alicia C. Saunders

Validation of the Autism Spectrum Screening Scale (ASSQ), Mandarin Chinese Version 762

Yilang Tang

Maternal Involvement Moderates Relations between COMT Polymorphism and Child Psychopathology.......................................763Matthew D. Albaugh

Psychiatric Disorders in Youth with 22q11.2 Deletion Syndrome.....................................764Edith M. Jolin

Serotonin Receptor Genes are Associated with Treatment Response and Symptom Severity in Adults with ADHD....................765Frederick W. Reimherr

Association of Polymorphisms of the Serotonergic Pathways with Suicidality and Impulsive-Aggression in Adolescents: A Multi-Center Study.....................................766Gil Zalsman

Pontine Raphé and Habenular Functional Connectivities: Effect of Tryptophan Depletion....................................................767Ronald M. Salomon

Decreased Entorhinal Cortex Volume Among Patients with Major Depressive Disorder. .768Marsal Sanches

Possible Influence of Duration of Illness on the Volume of Prefrontal Cortex Structures in Major Depressive Disorder........................769Marsal Sanches

Negative Correlations between the Medial Orbitofrontal Cortex Volume and Anxiety Symptoms among Patients with Major Depressive Disorder...................................770Marsal Sanches

Limbic System Morphometry in Unaffected Relatives of Patients with Bipolar Disorder: An Automated Brain Image Segmentation and Volumetry Approach...........................771Marsal Sanches

Nicotinic Acetylcholine Receptor Dysfunction in Acutely Depressed Subjects with Major Depressive Disorder................772Aybala SaricicekNetwork Dysfunction in Late-Life Depression.................................................773Claire E. Sexton

Prefrontal Grey Matter Volume Abnormalities in Adolescent First Episode Mania............774Manpreet K. Singh

63

Monoamine Oxidase-A Binding Levels are Associated with Adaptive and Maladaptive Personality Traits.......................................775Alexandra Soliman

Quantitative [C-11]DASB PET Study of Serotonin Transporter (5-HTT) Binding in Healthy Volunteers: Effects of Sex, Age, and 5-HTTLPR Genotype..................................776Gregory M. Sullivan

Learning and Memory among Individuals with Major Depressive Disorder as Measured by CVLT-II and an fMRI Paradigm.............777Sara J. Walker

Modulation Effect of Rumination Trait and Low Tryptophan on Default-Mode Network Connectivity...............................................778Lihong Wang

Childhood Physical Abuse is Associated with Dampened Cortisol Stress Response in Adulthood...................................................779Linda L. Carpenter

HPA Axis Dysfunction in Remitted Bipolar Patients.......................................................780Fabrice Duval

Difference Between Morning and Evening TRH Tests Could Predict Antidepressant Response....................................................781Fabrice Duval

CSF MHPG and the DST as Predictors of Suicide Risk................................................782Jussi Jokinen

Stress Response in the Offspring of Suicide Attempters: Preliminary Findings.............783John G. Keilp

A Modified Social Stress Task for High-Risk Populations................................................784John G. Keilp

Elevated Corticotropin Releasing Hormone (CRH) during Pregnancy and Risk of Postpartum Depression.............................785Samantha Meltzer-Brody

Tryptophan Pathway Changes in Mood Disorders: Genetic and Biochemical Aspects.......................................................786Aye-Mu Myint

Gender Differences in Serum Cortisol Levels among Patients with Major Depressive Disorder......................................................787Marsal Sanches

Relationship between C-Reactive Protein and Atypical Depression Scores is not Altered by Gonadal Steroid Levels..............................788Debra A. Scrandis

HPT Axis and Exposure to Violence in Childhood in Suicide Attempters..............789Cave Sinai

Childhood Maltreatment and Adult Inflammation in Patients with Major Depression.................................................790Sara Zeugmann

Double-Blind Optimization of Subgenual Cingulate- Stimulation Parameters for Treatment Resistant Depression...............791Swati Chavda

Transcranial Magnetic Stimulation Coil Placement and Antidepressant Response: An Anatomical Magnetic Resonance Imaging Study...........................................................792Gary M. Hasey

Reasons for Exclusion from a Clinical Trial of Deep Brain Stimulation for Treatment-Resistant Depression: A Comparison between Unipolar and Bipolar Depressed Patients.......................................................793Paul E. Holtzheimer

Meta-Analysis of the Cognitive Side-Effects of Electroconvulsive Therapy....................794Declan M. McLoughlin

Improvement in Memory Deficits Following Computer Assisted Cognitive Remediation in Patients with a Mood Disorder..................795Liesel-Ann C. Meusel

Therapeutic Application of Navigation-Guided Repetitive Transcranial Magnetic Stimulation (rTMS) to Major Depression and rTMS-Induced Alteration of Gray Matter Volume........................................................796Motoaki Nakamura

Cognition and Functional Health Among Patients with Bipolar Depression, Mania, and Euthymia.............................................797Kelly A. Ryan

64

Relationship between the Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) and Blood Flow Changes in the Subgenual Anterior Cingulate Region in the Treatment for Major Depression................798Shun Takahashi

Repeated Electroconvulsive Shocks Decrease Firing Activity of Rat Ventral Tegmental Area Dopamine Neurons but not Locus Coeruleus Norepinephrine Neurons....................................................................799Peter Tsen

The C-RAT: A Comprehensive Risk Assessment Tool for Use before Prescribing Psychotropics............................................800Cletus S. Carvalho

Brazilian Psychiatric Brain Bank: A New Contribution Tool to Network Studies......801Kátia C. de Oliveira

Cortical Evoked Potentials in Response to Deep Brain Stimulation for Depression. . . .802John T. Gale

Longitudinal Follow-Up and Prediction of Antidepressant Efficacy of A 2-week Add-On rTMS Trial in Medication-Resistant Depression Using Cerebral Glucose Metabolism.................................................803Tung-Ping Su

Safety and Feasibility of rTMS in Adolescents with Depression....................804Christopher A. Wall

EEG Predictors of Response in Patients with Major Depression receiving rTMS.............805Paul Zarkowski

Nimodipine in the Treatment of Bipolar Disorder......................................................806Haroon R. Chaudhry

An Open Prospective Trial of Aripiprazole in Children and Adolescents with Bipolar I Disorder......................................................807Arman Danielyan

Initial Antidepressant Response to an N-methyl-D-aspartate Antagonist in ECT-Resistant Major Depression.......................808Lobna Ibrahim

Instability of Serum Lithium Level/Dose Ratio Predicts Affective Episode Recurrence in Bipolar I Disorder.......................................809Lobna A. Ibrahim

Predicting Response to SSRI Treatment for MDD: A Pilot Study Using Machine Learning Analysis of EEG Data.................................810Ahmad Khodayari-Rostamabad

Expectancy Effects and the Treatment of Depression: Cognitive and Neural Mechanisms................................................811Bret R. Rutherford

The Impact of Ramadan Fasting on Psychiatric Illness and Treatment -Implications to Clinical Care......................812Pavitra Kalmane Sridhara

Interference with D2 Dopamine Receptor β-Arrestin 2 Signaling May Relate to the Antimanic Effects of Cariprazine...............813Nika Adham

Brain Distribution and Binding of 11C-Cariprazine: In Vivo PET Studies in Non-Human Primates and Whole Hemisphere Postmortem Autoradiographic Studies in Human Brain Slices....................................814Nika Adham

Dynamic Alteration of Anhedonia-Related Behavior and Hippocampal Synaptosome N-Methyl-D-Aspartate Receptor Subunits Following Serotonin Depletion and Ketamine Treatment....................................................815Daniel R Austin

One Week Tolcapone Treatment in Psychotic Patients: Effects on Gating, Working Memory and Clinical Picture....................................816Evangelia M Tsapakis

Role of Glial Glutamate Transporter GLT1 (EAAT2) in the Antidepressant Action of Riluzole and Ceftriaxone............................817Mounira BanasrSelective Serotonergic Properties of Low-Dose Pipamperone May Enhance Antidepressant Effect: Preclinical Evidence.....................................................818Erik Buntinx

The Expression of Vgf is Reduced in Leukocytes of Depressed Patients and it is Restored by Effective Antidepressant Treatment....................................................819Annamaria Cattaneo

65

Mitochondrial Respiration, Transport, Fusion and Fission: Meeting High Energy Demands at the Synapse Using Mood Stabilizers. . . .820Maria D Corena

In Vitro Characterization of Vilazodone as a Dual-Acting Serotonin Reuptake Inhibitor and 5-HT1A Receptor Partial Agonist.........821John H. Kehne

Electrophysiological Assessment of Accelerated 5-HT1A Autoreceptor Desensitization in Rats Produced by Vilazodone, a Novel Serotonin Reuptake Inhibitor and 5-HT1A Receptor Partial Agonist.......................................................822John H. Kehne

In Vivo and Ex Vivo Characterization of Vilazodone as a Serotonin Reuptake Inhibitor and 5-HT1A Receptor Partial Agonist.........823John H. Kehne

Characterization of Tritiated k-Opoid Receptor Ligand, [3H]-GR103545 with In Vivo Occupancy in Rat Brain.............................824Teng Peng

Effect of Chronic Lithium Treatment on Morphology of Dendrites in Hippocampus and Prefrontal Cortex.................................825Seong S Shim

Partial Lesions of the Locus Coeruleus in Mice Reduce Depression and Modify the Effects of α-Adrenoceptor Stimulation and Blockade.....................................................826Eric A. Stone

Antidepressant-Like Effects of AMPA in an Animal Model of Depression.....................827Yousef Tizabi

Roles of Voltage-Dependent L-Type Calcium Channels in Behavioral Regulation Related to Bipolar Mood Disorder..........................828Tyson Tragon

The Inhibitory Effect of Antidepressants on Platelet Activation......................................829Yu-Lun Tseng

Intracellular pH in Olfactory Neuroepithelial Cells Derived from Bipolar Subjects and Psychiatrically Normal Controls................830Yonglin Gao

Bcl-2 Polymorphism rs956572 Modifies Disrupted Ca2+ Homeostasis in Bipolar Disorder......................................................831Jerry J. Warsh

Chronic Oxidative Stress Modulates TRPC3 and TRPM2 Channel Expression: Relevance to Bipolar Disorder.....................................832Jerry J Warsh

Higher Scores on Motor Impulsivity and Lower Scores on Cooperativeness are Associated with History of Suicide Attempts in Brazilian Outpatients with Bipolar Disorder......................................................833Karla Almeida

Lithium Prevents Nitration and Oxidation in Mitochondrial but not in Non-Mitochondrial Proteins......................................................834Ana Cristina Andreazza

Chronic Administration of the D2 Receptor Agonist Pramipexole Enhances Serotonin and Dopamine Neurotransmission............835Olga Chernoloz

Trazodone Acts as a Serotonin (5-HT) Reuptake Inhibitor and 5-HT1A Receptor Agonist on the 5-HT System......................836Ramez Ghanbari

Citalopram Pre-Treatment Does Not Reduce Endotoxin-Induced Depressive Symptoms....................................................................837Jonas Hannestad

Differences in Brain Connectivity between Genders......................................................838Melissa P. Lopez-Larson

Attenuated White Matter Integrity is Associated with Increased Depressive Symptoms in Adolescents: Evidence from the Teen Alcohol Outcomes Study (TAOS)....................................................................839Douglas E. Williamson

A Rapid, Reversible Neural Plasticity Mechanism in Humans Predicts Acute Extrapyramidal Side Effects......................840Heike Tost

Excessive Players of First Person Shooter Games Show Activity Differences in Frontal

66

Brain Areas During Processing of Emotional Pictures.......................................................841Gregor R. Szycik

The Effect of Short and Long-term Ovariectomy and Hormone Replacement on Fenfluramine-Induced Prolactin Secretion in Macaques....................................................842Cynthia L. Bethea

Neurocognition and Temperament in Borderline and Schizotypal Personality Disorder......................................................843Heather A. Berlin

Probabilistic and Delay Discounting Related to Psychopathic Traits...............................844Hiroki Fukui

Replicated Association of Single Nucleotide Polymorphisms in the DRD2 and ANKK1 Genes with Prolactin Increases in Olanzapine-Treated Women......................845Jeffrey R. Bishop

BDNF and TPH2 are Associated with Personality Disorder in Adults with Attention-Deficit Hyperactivity Disorder. . .846John L Olsen

Tryptophan Hydroxylase 2 Haplotype in Predicting Borderline Personality Disorder......................................................847M. Mercedes Perez-Rodriguez

Evidence Increased 5-HT2A Receptor Availability in the Orbitofrontal Cortex is Associated with Impulsive Physical Aggression in a State Dependent Manner........................................................848Daniel R. Rosell

Functional Connectivity in Fronto-Limbic Networks in Un-Medicated Women with Borderline Personality Disorder................849Kathryn R. CullenTrust and Fear Appraisal in Borderline Personality Disorder: Preliminary Psychophysical and Neural Findings.......850Eric A. Fertuck

The Structural Phenotypes of Persistent Violence: A Nipa Structural Mri Study.......851Sarah L Gregory

Fronto-Temporal Fractional Anisotropy Abnormalities and Symptom Correlates in Schizotypal Personality Disorder..............852Erin A Hazlett

Social Cognition and Emotional Empathy in Borderline and Narcissistic Personality Disorder: Behavioral and fMRI Data..........853Stefan Roepke

Amygdala BOLD Activity Predicts Dialectical Behavior Therapy Response in Borderline Personality Disorder..................................854Marianne Goodman

Gender Differences in Patients with Borderline Personality Disorder................855Anke Rüter

Comparative Analysis of Cortical Thickness Differentiates Children with Atypical Psychosis from Childhood-Onset Schizophrenia............................................856Jennifer L. Bakalar

Increased Anhedonia in Adolescent Schizophrenia Offspring Predicts Hypo-Responsivity of Subgenual Frontal Cortex to Positive Stimuli..........................................857Tracy Barbour

Enhanced Emotional Threat Perception and Right Cerebral Hemispheric Dysfunction in Antipsychotic Naive Schizophrenia..........858Rishikesh V. Behere

The Resting rCBF Profile as a Predictor of Neuropsychological Performance.............859Anees Benferhat

Signal Detection Theory Identifies Subjects with Shared Characteristics in Schizophrenia............................................860Will Cronenwett

Glutamate Levels in the Associative Striatum of Antipsychotic-Naïve First Episode Psychotic Patients and Subjects with Prodromal Symptoms of Schizophrenia. . .861Camilo de la Fuente-SandovalfMRI Response to Experimental Pain in Drug-Free Patients with Schizophrenia..............862Camilo de la Fuente-Sandoval

Glutamate Quantification in the Associative Striatum of Patients with Schizophrenia before and after Antipsychotic Treatment....................................................863Camilo de la Fuente-Sandoval

Ketamine: Schizophrenia In A Bottle? .....864Judith M. Ford

67

Failure of Normal Aging-Related Hemispheric Asymmetry Reduction in Brain Activity During Target Detection in Schizophrenia............................................865Daniel H. Mathalon

Frontal Lobe Structure as an Imaging Phenotype of Psychosis............................866Jean A. Frazier

Polymorphisms of the Alpha7 Nicotinic Cholinergic Receptor (chrna7) Discriminate Figural Memory Abilities in Healthy Controls......................................................867Kanchana Jagannathan

Altered Activation in Association with Reward-Related Trial-and-Error Learning in Patients with Schizophrenia......................868Kathrin Koch

Association between Severer Dorsolateral Prefrontal Dysfunction During Random Number Generation and Earlier Onset in Schizophrenia............................................869Shinsuke Koike

Extensive White Matter Abnormalities in First-Episode Schizophrenia: A Voxel-Based Diffusion Tensor Imaging..........................870Sang-Hyuk Lee

Anterior Cingulate Gyrus and Paracingulate Sulcal Patterns in Schizophrenia: An MRI Study...........................................................871James J. Levitt

Normalization of Gray Matter Deficits in Nonpsychotic Siblings of Patients with Childhood-Onset Schizophrenia...............872Anand Mattai

A Large Scale (N=351) Analysis of Resting State Functional Network Connectivity in Schizophrenia & Psychotic Bipolar Probands and their Unaffected Relatives...................873Shashwath A. Meda

White Matter Complexity Abnormalities in Schizophrenia using Q-Ball Imaging........874Ryan L Muetzel

Abnormalities in White Matter Connectivity between Orbitofrontal Cortex and Anterior Cingulate Cortex in Schizophrenia............875

Toshiyuki Ohtani

Alterations of White Matter Integrity in Deficit Schizophrenia............................................876Shauna M. Overgaard

Abnormal Development of White Matter Tracts in Children and Adolescents with First Episode Psychosis.....................................877Soledad Romero

Regional Temporal Lobe Gray Matter Volumes and Memory Functioning in Youth at Familial Risk for Schizophrenia from the Harvard Adolescent High Risk Study........878Isabelle M. Rosso

Abnormal Cognitive Control Processing in Unaffected Siblings of Patients with Schizophrenia: An Fmri Intermediate Phenotype for Schizophrenia?..................879Fabio Sambataro

Diffusion Tensor Imaging of the Uncinate Fasciculus in First Episode Schizophrenia............................................880Jason S. Schneiderman

Altered Resting State EEG Connectivity in Schizophrenia: An ICA Based Study.........881Ritu Sharma

Increased Temporal Variability of Auditory Event Related Potentials in Schizotypal Personality Disorder..................................882Yong Wook Shin

White Matter Development in Siblings of Patients with Childhood-Onset Schizophrenia Visualized Using Tensor-Based Morphometry..............................................883Reva Stidd

Longer Duration of Untreated Psychosis is Associated with Severer Dorsolateral Prefrontal Hemodynamic Abnormalities in Schizophrenia: A Functional NIRS Study. 884Ryu Takizawa

Event-Related Potential Study of Preattentive Visual Processing in Schizophrenia.........885Shoji Tanaka

Comparison of Progressive Hippocampal Volume Change in Childhood-Onset Schizophrenia and Their Nonpsychotic Siblings.......................................................886

68

Brian Weisinger

Inter-Hemispheric Transfer Time and White Matter Integrity in Schizophrenia: A Combined ERP and DTI Study...................887Thomas J. Whitford

Left Fusiform Gyrus Grey Matter Volume as a Candidate Endophenotype of First Episode Psychosis...................................................888Anna M. Wilson

A Voxel-Based Morphometry Study of Shared and Distinct Abnormalities in Grey Matter Density in Psychotic Disorders.................889A. Cagri Yuksel

Thyrotropin (TSH) Reference Range in Acute and Ambulatory Psychiatric Patients........890Osama A. Abulseoud

The Effect of Childhood Trauma and Antipsychotic Treatment on Inflammatory and Metabolic Markers in First-Episode Psychosis...................................................891Valeria Mondelli

25-OH Vitamin D Deficiency is Associated with Psychotic Features in Acutely Mentally Ill Adolescents............................................892Barbara L. Gracious

Coping Styles of Individuals at Clinical High Risk for Developing Psychosis.................893Maria Jalbrzikowski

Pilot Studies of Adjunctive Cognitive Remediation for Schizophrenia.................894Vishwajit L. Nimgaonkar

Difficulty Maintaining an Emotion in Schizophrenia: A Laboratory-Based Behavioral Study........................................895Shanna Cooper

Reducing Cognitive Demand in Ecological Momentary Assessment in Schizophrenia: A Feasibility Study Using Cellular Telephones.................................................896Sunny G. Pence

Assessing Motivation in Schizophrenia....897Fabien Tremeau

Genetic Variation in CYP3A43 Explains Racial Difference in Olanzapine Clearance898Kristin L. Bigos

Fast Off-Rate Dopamine D2 Receptor Antagonists are well Tolerated by Healthy

Subjects Despite High Levels of Central Dopamine D2 Receptor Occupancy...........899Peter De Boer

Increases in Cerebrospinal Fluid Glycine Levels are not Associated with Psychomotor Functioning in Healthy Subjects Following Administration of an Inhibitor of the Glycine Reuptake Transporter-1.............................900Peter De Boer

Glutathione Precursor, N-Acetyl-Cysteine, Modulates EEG Synchronization in Schizophrenia Patients..............................901Kim Q. Do

Single Dose Tolcapone Administration Improves Working Memory and Sensorimotor Gating in Psychotic Patients....................................................................902Stella Giakoumaki

The Selective NK3 Antagonist AZD2624 Does Not Improve Symptoms or Cognition in Schizophrenia............................................903Robert E. Litman

Pharmacological Treatment of Insight Deficits in Schizophrenia...........................904Mujeeb U Shad

Antipsychotic Medications Dose-Dependently Increase Postprandial Rat Plasma Triglyceride and Glucose Levels: Dissociation from Stearoyl-CoA Desaturase Activity........................................................905Robert K. McNamara

Antipsychotic Medications Dose-Dependently Increase Rat Erythrocyte Polyunsaturated Fatty Acid Composition: Evidence for Increased Delta-6 Desaturase Activity........................................................906Robert K. McNamara

Sensorimotor Gating of Neurotensin-1 Receptor and Neurotensin-2 Receptor Null Mice: Neurotensin-1 Receptor is Essential for d -Amphetamine and Dizocilpine Induced Disruption of Pre-Pulse Inhibition.............907Alfredo Oliveros

Effect of Neurotensin Agonists on Protein Expression in the Mouse Brain.................908Kristin E. Smith

Differential Impact of GAD67 Deficiency on Inhibitory Synaptic Transmission in Primary Visual vs. Prefrontal Cortex in Mice..........909

69

Matthew S. Lazarus

Using TMS /hd-EEG to Explore the Natural Oscillatory Frequency of Cortical Areas in Schizophrenia............................................910Fabio Ferrarelli

Correlation between Prepulse Inhibition and Frontal Hemodynamic Responses during a Verbal Fluency Task in Schizophrenia: A Near-Infrared Spectroscopy (NIRS) Study...........................................................911Shinichi Yamada

Abnormalities in Postural Sway Area and Complexity in Schizophrenia Spectrum Participants................................................912Jerillyn S. Kent

NMDA Receptor Hypofunction in the Auditory Cortex in Schizophrenia.............913Ryan P. Mears

Predictors of Response to Neuroplasticity-Based Cognitive Training in Schizophrenia............................................914Melissa A. Fisher

Deep Brain Stimulation of the Nucleus Accumbens in Treatment Resistant Alcohol Addiction - A Novel Treatment Option?....915Ulf J. Mueller

Development and Validation of the Monell Craving Inventory.......................................916Julia M. Hormes

Acoustic Startle Reduction in Cocaine Dependence................................................917Sarah Corcoran

Combined Pergolide and Ondansetron Treatment Attenuates Cocaine-Induced Reinstatement of Self-Administration and Normalize Associated Increase in Total Protein Expression Protein Kinase C Zeta (PKC ζ)........................................................918Colin Davidson

Rapid Extinction of Morphine Conditioned Place Preference in C57BL/6 Mice: Effects of D-Cycloserine.............................................919Gary B. Kaplan

SHA-68, a Selective Neuropeptide S Receptor Antagonist, Mediates Glutamate Release in

the Nucleus Accumbens, and Drug Seeking and Withdrawal Behaviors in Rodents......920James R. Shoblock

Reversal of Consolidated Behavioral Sensitization and Associated Neurochemical Changes by Local Infusion of PKC Zeta (ζ) Inhibitory Pseudosubstrate (ZIP) Peptide in Nucleus Accumbens Core.........................921Steven T. Szabo

Temporal Dynamics of Prefrontal Responses to Emotion Following Response to Antidepressant and Cognitive Behavioral Therapies for Unipolar Depression...........922Greg J. Siegle

Gene Expression Changes in Response to Citalopram Treatment in Patients with Major Depressive Disorder...................................923Gustavo Turecki

Investigating the Differential Neural Substrates of Brief and Sustained Emotional Responses..................................................924Tor D. Wager

Poster Session – Late-BreakingSaturday, May 225:00 PM - 6:30 PMGrand Ballroom DE – 5th Floor

At the time of publication, these abstracts were not available to include in the program book. Please see the On-Line Program Planner at www.sobp.org to view the abstract.

Low Field Magnetic Stimulation as Treatment for Depressions: Thresholds in the Forced Swim Test ..................................................925Rinah T. Yamamoto

Transcriptome And Genome-wide Association Data Implicate Piccolo Gene In Bipolar Disorder ........................................926Kwang H. Choi

Low Field Magnetic Stimulation as a Treatment for Depression: Initial Study with a New Device ................................................927Michael L. Rohan

Association between Inflammatory Cytokines and Brain-Derived Neurotrophic Factor among Adolescents with Bipolar Disorder .....................................................928Benjamin I. Goldstein

70

Core Physiological Findings In Depression And Suicidality Recapitulated In A Naturalistic Mouse Model Of 5-ht-deficiency ....................................................................929Jacob P. R. Jacobsen

Left Intentially Blank..................................930

A Low-Activity Allele of Dopamine β-Hydroxylase Gene (DBH -1021 C→T) Has a Protective Effect for Alcohol Dependence in a Thai Substance Dependence Treatment Cohort ........................................................931Rasmon Kalayasiri

Toxoplasma gondii and Suicidal Behavior ....................................................932Teodor T. Postolache

Ketamine Produces Rapid and Long-Lasting Effects in Pre-natally Stressed Rats resistant to a SSRI ....................................................933Carla Maciag

Early Intervention In A Hypoglutamatergic Model With Relevance To Schizophrenia  934Neil Richtand

Incidents Of Suicide Death Are Associated With Pollen Counts In The Environment: A Study Based On Danish Longitudinal Data ............................................................935Ping Qin

Lithium's Antidepressant-like Effects Are Mouse Strain Dependent: A Model for the Clinical Efficacy Of Lithium ......................936Adem Can

Distinct Receptor Mechanisms Underlying Acute and Repeated Effects of Haloperidol, Clozapine and Olanzapine in the Rat Avoidance Conditioning Model ................937Ming LiCase Control Association Study Reveals Candidate Gene NTNG1e3 as Highly Associated with Schizophrenia in Mexican Population .................................................938James Wilcox

Dinucleotide Microsatellite Polymorphism of DRD 2 Gene and Subtypes of Alcoholism.................................................939Jolanta Kucharska Mazur

Depression is an Inflammatory Disease Characterized by an Autoimmune Response Mounted against Neoepitopes Formed by Damage to Membrane Fatty Acids, through Oxidation, and Proteins, through

Nitration......................................................940Michael Maes

Low Field Magnetic Stimulation and the Fields of MRI Gradient Coils: Electric Fields in the Cortex  .............................................941Michael L. Rohan

Dopaminergic System Genes Polymorphisms are not Associated with Clinical Response to Antipsychotic Drugs in Schizophrenic Patients ......................................................942Jerzy Samochowiec

Effect of Agmatine on Cognitive Functions in Rats ............................................................943Feyza Aricioglu

Stress and Some Psychotropic Drugs Influence Cell Proliferation in the Heart of Rats.............................................................944Maria Ondrejcakova

SAT-1 -1415T/C Polymorphism and Suicidal Behavior ....................................................945Carlos Riaza

Ceftriaxone Blocks Methamphetamine-Triggered Reinstatement of Conditioned Place Preference in Rats ........................................................946Osama A. Abulseoud

SAT-1 rs1960264 Polymorphism and Suicidal Behavior ....................................................947Carlos Riaza

Dopamine 4 Recepter Gene Polymorphism Association and Drug Response in Tourette Syndrome ..................................................948Myung Ho Lim

71